Skip to main content
Research

Publications: Prof Jack Cuzick

Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F et al. ( 2020 ) . Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer . Clin Cancer Res vol. 26 , ( 17 ) 4682 - 4687 .
Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, Goldberg DW, Scarinci IC et al. ( 2020 ) . Impact of screening on cervical cancer incidence: A population-based case-control study in the United States . Int J Cancer vol. 147 , ( 3 ) 887 - 896 .
French DP, Astley S, Astley S, Brentnall AR, Cuzick J, Dobrashian R, Duffy SW, Gorman LS et al. ( 2020 ) . What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420) . BMC Cancer vol. 20 , ( 1 )
Britt KL, Cuzick J, Phillips K-A ( 2020 ) . Key steps for effective breast cancer prevention . Nat Rev Cancer
Ramírez-Palacios P, Chen A, Flores YN, Crespi CM, Lazcano-Ponce E, Alvarez-Escobedo D, Torres-Ibarra L, Rivera-Paredez B et al. ( 2020 ) . Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus-positive women in Mexico . Cancer Cytopathol
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, Kim J, Poljak M et al. ( 2020 ) . Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) . Br J Cancer
Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, Stoler MH, Ronnett BM et al. ( 2020 ) . Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology . Arch Pathol Lab Med vol. 144 , ( 6 ) 725 - 734 .
Renehan AG, Pegington M, Harvie MN, Sperrin M, Astley SM, Brentnall AR, Howell A, Cuzick J et al. ( 2020 ) . Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom) . British Journal of Cancer vol. 122 , ( 10 ) 1552 - 1561 .
Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, Sampson S, Howell A et al. ( 2020 ) . A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density . International Journal of Cancer vol. 146 , ( 8 ) 2122 - 2129 .
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al. ( 2020 ) . 10-year results of the International Breast Cancer Intervention Study II (IBIS-II) . BREAST CANCER RESEARCH AND TREATMENT . Conference: UKIBCS vol. 180 , 527 - 527 .
Hale MJ, Cuzick J, Sestak I ( 2020 ) . A genome-wide association study of vaginal discharge during tamoxifen therapy for breast cancer prevention . BREAST CANCER RESEARCH AND TREATMENT . Conference: UKIBCS vol. 180 , 570 - 571 .
Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, Cuzick J ( 2020 ) . Correlations between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: a TransATAC study . BREAST CANCER RESEARCH AND TREATMENT . Conference: UKIBCS vol. 180 , 543 - 543 .
Dobson R, Jitlal M, Marshall CR, Noyce AJ, Robson J, Cuzick J, Giovannoni G ( 2020 ) . Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk . Annals of Neurology vol. 87 , ( 4 ) 599 - 608 .
Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M ( 2020 ) . Prognostic value of EndoPredict and oncotype recurrence score according to patients' age . BREAST CANCER RESEARCH AND TREATMENT . Conference: UKIBCS vol. 180 , 580 - 580 .
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J ( 2020 ) . Validation of the Clinical Treatment Score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study . BREAST CANCER RESEARCH AND TREATMENT . Conference: UKIBCS vol. 180 , 532 - 533 .
Dobson R, Jacobs B, Giovannoni G, Cuzick J ( 2020 ) . Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors . Multiple Sclerosis Journal
Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A, Frayle H, Girlando S et al. ( 2020 ) . Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening . Int J Cancer
Brentnall AR, Cuzick J ( 2020 ) . Risk Models for Breast Cancer and Their Validation . Statistical Science: a review journal vol. 35 , ( 1 ) 14 - 30 .
Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B et al. ( 2020 ) . Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics . International Journal of Cancer vol. 146 , ( 4 ) 1018 - 1030 .
Sasieni P, Cuzick J ( 2020 ) . Population-level impact of human papillomavirus vaccination . Lancet vol. 395 , ( 10222 )
Li H, Bera K, Gilmore H, Zhang Z, Cuzick J, Thorat MA, Madabhushi A ( 2020 ) . Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS) . CANCER RESEARCH . vol. 80 ,
Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel C, Baehner FL, Cuzick J ( 2020 ) . Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study . CANCER RESEARCH . Conference: SABCS vol. 80 ,
Sestak I, Ferree S, Shemesh I, Buckingham W, Cuzick J, Dowsett M ( 2020 ) . Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer . CANCER RESEARCH . Conference: SABCS vol. 80 ,
Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M ( 2020 ) . Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age . CANCER RESEARCH . Conference: SABCS vol. 80 ,
Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B et al. ( 2020 ) . Ten year results of the international breast cancer intervention study II . CANCER RESEARCH . Conference: SABCS vol. 80 ,
Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CJA et al. ( 2020 ) . Validation of the OncoMASTR risk score in estrogen receptor–positive/HER2-negative patients: A TransATAC study . Clinical Cancer Research vol. 26 , ( 3 ) 623 - 631 .
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J ( 2020 ) . Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study . CANCER RESEARCH . Conference: SABCS vol. 80 ,
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al. ( 2020 ) . Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial . Lancet vol. 395 , ( 10218 ) 117 - 122 .
Wang C, Brentnall AR, Mainprize J, Yaffe M, Cuzick J, Harvey JA ( 2020 ) . External validation of a mammographic texture marker for breast cancer risk in a case-control study . Journal of Medical Imaging vol. 7 , ( 1 )
Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P et al. ( 2020 ) . Personalized early detection and prevention of breast cancer: ENVISION consensus statement . Nature Reviews Clinical Oncology
Dench E, Bond-Smith D, Darcey E, Lee G, Aung YK, Chan A, Cuzick J, Ding ZY et al. ( 2019 ) . Measurement challenge: Protocol for international case-control comparison of mammographic measures that predict breast cancer risk . BMJ Open vol. 9 , ( 12 )
Phillips K-A, Liao Y, Milne RL, MacInnis RJ, Collins IM, Buchsbaum R, Weideman PC, Bickerstaffe A et al. ( 2019 ) . Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool . JNCI Cancer Spectr vol. 3 , ( 4 )
Noyce AJ, Bandres-Ciga S, Kim J, Heilbron K, Kia D, Hemani G, Xue A, Lawlor DA et al. ( 2019 ) . The Parkinson's Disease Mendelian Randomization Research Portal . Movement Disorders vol. 34 , ( 12 ) 1864 - 1872 .
Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki AB, Mahmud SM et al. ( 2019 ) . Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico . JAMA network open vol. 2 , ( 11 ) e1915781 - e1915781 .
Sun L, Brentnall A, Patel S, Buist D, Bowles E, Evans DG, Eccles D, Hopper J et al. ( 2019 ) . SHOULD WE OFFER MULTI-GENE TESTING TO ALL PATIENTS WITH BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS . INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . vol. 29 , A31 - A32 .
Biganzoli L, Marotti L, Cardoso M-J, Cataliotti L, Curigliano G, Cuzick J, Goldhirsch A, Leidenius M et al. ( 2019 ) . European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes . Breast Care vol. 14 , ( 6 ) 359 - 365 .
Nedjai B, Hernández-López R, Lorincz A, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, Mendiola-Pastrana I et al. ( 2019 ) . Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping . Clinical Epigenetics
Nedjai B, Reuter C, Toni H, Austin J, Cadman L, Cuzick J, Lorincz A ( 2019 ) . Non-invasive methylation test to detect cervical pre-cancer in self-collected vaginal and urine specimens . BRITISH JOURNAL OF CANCER . vol. 121 , 12 - 12 .
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J et al. ( 2019 ) . A Cost-effectiveness Analysis of Multigene Testing for All Patients with Breast Cancer . JAMA Oncology
Sun L, Brentnall A, Patel S, Buist SM D, Bowles JA E, Evans R DG, Eccles D, Hopper J et al. ( 2019 ) . 66 Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis . Regional plenary
Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G, Beltran L, Cuzick J et al. ( 2019 ) . Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments . Modern Pathology vol. 32 , ( 9 ) 1303 - 1309 .
Soliman H, Flake DDII, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S et al. ( 2019 ) . Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay . JCO Precision Oncology
Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE et al. ( 2019 ) . Screening performance of abbreviated versions of the UPSIT smell test . J Neurol vol. 266 , ( 8 ) 1897 - 1906 .
Brenner A, Afolabi A, Ahmad SM, Arribas M, Chaudhri R, Coats T, Cuzick J, Gilmore I et al. ( 2019 ) . Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial . Trials vol. 20 , ( 1 )
Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R ( 2019 ) . Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia . Bone vol. 124 , 83 - 88 .
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al. ( 2019 ) . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 . Ann Oncol vol. 30 , ( 7 )
Cuzick J ( 2019 ) . Predicting late recurrence in ER-positive breast cancer . Nat Rev Clin Oncol vol. 16 , ( 7 ) 406 - 408 .
Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG et al. ( 2019 ) . Prediction of reader estimates of mammographic density using convolutional neural networks . Journal of Medical Imaging vol. 6 , ( 3 )
Sestak I, Zhang Y, Schnabel CA, Cuzick JM, Dowsett M ( 2019 ) . Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 37 ,
Cuzick JM, Stone S, Rajamani S, Moller H, Berney DM, Cohen T, Scardino PT ( 2019 ) . Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP . JOURNAL OF CLINICAL ONCOLOGY . vol. 37 ,
Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ et al. ( 2019 ) . Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial . International Journal of Cancer vol. 144 , ( 10 ) 2587 - 2595 .
Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA ( 2019 ) . A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model . Journal of Breast Imaging vol. 1 , ( 2 ) 99 - 106 .
Sestak I, Filipits M, Buus R, Rudas M, Knauer M, Kronenwett R, Cuzick J, Gnant MI et al. ( 2019 ) . Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials . ANNALS OF ONCOLOGY . Conference: ESMO Breast vol. 30 ,
SESTAK IVANA, CUZICK J ( 2019 ) . Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone . Breast Cancer Research and Treatment
Berney DM, Beltran L, Sandu H, Soosay G, Møller H, Scardino P, Murphy J, Ahmad A et al. ( 2019 ) . The percentage of high grade disease in prostate biopsies significantly improves on grade groups in prediction of prostate cancer death . Histopathology
Cuzick J, Brentnall A ( 2019 ) . Commentary on Terry et al., 10-Year Performance of Four Models of Breast Cancer Risk: A Validation Study. Lancet Oncol. 2019;20(4):504-17 . Med One vol. 4 , ( 2 )
Boddington C, Bradley R, Braybrooke J, Burrett J, Clarke M, Davies C, Davies L, Dodwell D et al. ( 2019 ) . Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials . LANCET vol. 393 , ( 10179 ) 1440 - 1452 .
Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J et al. ( 2019 ) . A response to "Personalised medicine and population health: breast and ovarian cancer" . Hum Genet vol. 138 , ( 3 ) 287 - 289 .
Dodson A, Sestak I, Bayani J, Dowsett M, Bartlett J, Cuzick J ( 2019 ) . A newly derived combined clinical treatment score and immunohistochemical-4 prognostic tool . CANCER RESEARCH . Conference: SABCS vol. 79 ,
Allen N, Allen M, Ahmed K, Gomm J, Nelan R, Nagano A, Chelala C, Gadaleta E et al. ( 2019 ) . Defining molecular signatures to personalise management of patients with early breast cancer . CANCER RESEARCH . Conference: 2018 San Antonio Breast Cancer Symposium from: 04/12/2019 to: 08/12/2019 , vol. 79 ,
Sestak I, Dowsett M, Cuzick J ( 2019 ) . Importance of adverse events during endocrine treatment for the prediction of late distant recurrences . CANCER RESEARCH . Conference: SABCS vol. 79 ,
Sestak I, Martin M, Dubsky P, Rojo F, Cuzick J, Filipits M, Ruiz A, Buus R et al. ( 2019 ) . Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET plus C) or endocrine therapy alone (ET) . CANCER RESEARCH . Conference: SABCS vol. 79 ,
Phillips K-A, Liao Y, Collins IM, Buchsbaum R, Weideman P, Bickerstaffe A, MacInnis RJ, Cuzick J et al. ( 2019 ) . Validation of iPrevent using the prospective family study cohort (ProF-SC) . CANCER RESEARCH . vol. 79 ,
Evans DGR, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, Sampson S, Southworth J et al. ( 2019 ) . Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants . Breast Cancer Research and Treatment
Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM ( 2019 ) . Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia . Cancer Epidemiology Biomarkers and Prevention vol. 28 , ( 11 ) 1816 - 1824 .
Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM et al. ( 2018 ) . Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry . Am J Surg Pathol
Brentnall AR, Buist DSM, Cuzick J ( 2018 ) . Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply . JAMA Oncol
Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN ( 2018 ) . Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention . Eur J Cancer Prev
Lo L, Collins I, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E et al. ( 2018 ) . Acceptability and Usability of iPrevent® , a Web-Based Tool for Assessment and Management of Breast Cancer Risk . JMIR Formative Research vol. 2 , ( 2 )
Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E et al. ( 2018 ) . The iPrevent online breast cancer risk assessment and risk management tool: Usability and acceptability testing . Journal of Medical Internet Research vol. 20 , ( 11 )
Sestak I, Cuzick J ( 2018 ) . Off-Treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole . JOURNAL OF BONE AND MINERAL RESEARCH . Conference: ASBMR vol. 33 , 102 - 103 .
Sestak I, Cuzick J, Blake G, Patel R, Coleman R, Eastell R ( 2018 ) . Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole . JOURNAL OF BONE AND MINERAL RESEARCH . Conference: ASBMR vol. 33 , 46 - 46 .
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al. ( 2018 ) . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 . Ann Oncol vol. 29 , ( 10 )
van Veen EM, Harkness EF, Brentnall AR, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J et al. ( 2018 ) . Improving breast cancer risk prediction by combining 18 SNPs, mammographic density and the Tyrer-Cuzick model . EUROPEAN JOURNAL OF HUMAN GENETICS . vol. 26 , 681 - 681 .
Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J et al. ( 2018 ) . Molecular progression to cervical precancer, epigenetic switch or sequential model? . International Journal of Cancer vol. 143 , ( 7 ) 1720 - 1730 .
Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I ( 2018 ) . Outcome measures in clinical trials of treatments for acute severe haemorrhage 11 Medical and Health Sciences 1103 Clinical Sciences . Trials vol. 19 , ( 1 )
Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q et al. ( 2018 ) . Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer . Breast Cancer Research vol. 20 , ( 1 )
Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H et al. ( 2018 ) . Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death . eLife vol. 7 ,
Atakpa EC, Thorat MA, Cuzick J, Brentnall AR ( 2018 ) . Mammographic density, endocrine therapy and breast cancer risk: A prognostic and predictive biomarker review . Cochrane Database of Systematic Reviews vol. 2018 , ( 8 )
Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG ( 2018 ) . Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews . Breast Cancer Research and Treatment vol. 170 , ( 3 ) 633 - 640 .
Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG et al. ( 2018 ) . Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment . Progress in Biomedical Optics and Imaging - Proceedings of SPIE . Conference: 14th International Workshop on Breast Imaging (IWBI 2018) ( Atlanta, Georgia, United States ) from: 11/07/2018 to: 08/07/2018 , vol. 10718 ,
Lo LL, Milne RL, Liao Y, Cuzick J, Terry MB, Phillips KA ( 2018 ) . Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ . British Journal of Cancer vol. 119 , ( 1 ) 36 - 39 .
Macis D, Sestak I, Aristarco V, Johansson H, Guerrieri-Gonzaga A, Decensi A, Bonanni B, Cuzick J et al. ( 2018 ) . Adiponectin, leptin and breast cancer in high risk postmenopausal women: Results from a nested case-control study . CANCER RESEARCH . Conference: AACR vol. 78 ,
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J ( 2018 ) . Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 . J Clin Oncol vol. 36 , ( 19 ) 1941 - 1948 .
Cuzick J ( 2018 ) . The Value of Helicobacter Eradication in Long-term Aspirin Users . J Natl Cancer Inst vol. 110 , ( 7 ) 690 - 691 .
Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S ( 2018 ) . Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds . Breast Cancer Research vol. 20 , ( 1 )
Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A et al. ( 2018 ) . Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance . Urologic Oncology: Seminars and Original Investigations vol. 36 , ( 6 ) 310.e7 - 310.e13 .
Sestak I, Buus R, Cuzick JM, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P et al. ( 2018 ) . Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 36 ,
Smith SG, Sestak I, Morris MA, Howell A, Forbes JF, Cuzick JM ( 2018 ) . Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 36 ,
Sestak I, Zhang Y, Sgroi D, Schnabel CA, Cuzick JM, Dowsett M ( 2018 ) . Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 36 ,
CUZICK JM ( 2018 ) . Prognosis vs Treatment Interaction . JNCI: Journal of the National Cancer Institute Cancer Spectrum vol. 2 , ( 1 )
CUZICK JM ( 2018 ) . Progress in Preventive Therapy for Cancer – A reminiscence and personal viewpoint . British Journal of Cancer
AHMAD AS, Parameshwaran V, Beltran L, FISHER G, Greenberg D, Soosay G, MOLLER H, Scardino P et al. ( 2018 ) . Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively . Oncotarget
BRENTNALL AR, CUZICK J, BUIST DSM, BOWLES EA ( 2018 ) . Long-term accuracy of breast cancer risk assessment combining classical factors and breast density: a cohort study . JAMA Oncology
Sgroi DC, Sestak I, Cuzick J ( 2018 ) . Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population (vol 14, pg 1067, 2013) . LANCET ONCOLOGY vol. 19 , ( 4 ) E184 - E184 .
Kammerer-Jacquet S-F, Ahmad A, Moller H, Scardino P, Beltran L, Cuzick J, Berney D ( 2018 ) . Ki-67 is an Independent Predictor of Prostate Cancer Death in Routine Sections: Potential Use in Active Surveillance . MODERN PATHOLOGY . vol. 31 , 354 - 354 .
Beltran L, North B, Moller H, Scardino P, Cuzick J, Berney D ( 2018 ) . Prognostic Value of Cancer Extent Assessment in a Conservatively Treated Prostate Biopsy Cohort of 988 Men Using Prostate Cancer Death as Outcome . LABORATORY INVESTIGATION . vol. 98 , 327 - 327 .
Mistro A, ADCOCK R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H et al. ( 2018 ) . Human papilloma virus genotyping for the cross‐sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more . International Journal of Cancer
SESTAK I, Buus R, CUZICK JM, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D et al. ( 2018 ) . Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer . JAMA Oncology
Phillips K-A, Lo L, Bressel M, Collins IM, Emery J, Weideman P, Keogh L, Steel E et al. ( 2018 ) . Abstract P4-11-02: Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk . Poster Session Abstracts
Astley SM, Harkness EF, Sergeant JC, WARWICK J, Stavrinos P, Warren R, Wilson M, Beetles U et al. ( 2018 ) . A comparison of five methods of measuring mammographic density: a case-control study . Breast Cancer Research
Phillips K-A, Lo L, Bressel M, Collins IM, Emery J, Weideman P, Keogh L, Steel E et al. ( 2018 ) . Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk . CANCER RESEARCH . vol. 78 ,
Sestak I, Regan M, Dodson A, Viale G, Thurlimann B, Colleoni M, Cuzick J, Dowsett M ( 2018 ) . Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy . CANCER RESEARCH . Conference: SABCS vol. 78 ,
Sestak I, Smith S, Sleeth M, Howell A, Cuzick J ( 2018 ) . Participant-reported symptoms as predictors of long-term adherence of endocrine therapy in the International breast cancer intervention studies 2 (IBIS-2) . CANCER RESEARCH . Conference: SABCS vol. 78 ,
Sestak I, Kronenwett R, Denkert C, Cuzick J, Dowsett M ( 2018 ) . Prognostic performance of EndoPredict in invasive lobular carcinoma . CANCER RESEARCH . Conference: SABCS vol. 78 ,
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y ( 2018 ) . Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence after Endocrine Therapy of ER+ Breast Cancer . Journal of the National Cancer Institute vol. 110 , ( 2 )
Evans DG, BRENTNALL AR, Harvie M, Astley S, Harkness E, Stavrinos P, Donnelly LS, Sampson S et al. ( 2018 ) . Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK . BMC Public Health
van Veen E, BRENTNALL AR, Byers H, Harkness E, Astley S, Sampson S, Howell A, Newman W et al. ( 2018 ) . Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction . JAMA Oncology
Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C et al. ( 2018 ) . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials . The Lancet Oncology vol. 19 , ( 1 ) 27 - 39 .
Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M et al. ( 2018 ) . RAZOR: A phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in premenopausal women at increased risk of breast cancer . Cancer Epidemiology Biomarkers and Prevention vol. 27 , ( 1 ) 58 - 66 .
Cuzick J, Brentnall A, Dowsett M ( 2017 ) . SNPs for breast cancer risk assessment . Oncotarget vol. 8 , ( 59 ) 99211 - 99212 .
Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM et al. ( 2017 ) . Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial . Lancet vol. 390 , ( 10108 ) 2143 - 2159 .
Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J ( 2017 ) . Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II . Ann Oncol
Prasher S, Oliver T, Chinegwundoh F, Bhudia R, Cuzick J, Wilks M ( 2017 ) . Identification of low oxygen tolerating bacteria in prostate secretions of cancer patients: aetiological and therapeutic relevance . LANCET . vol. 390 , S71 - S71 .
Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S ( 2017 ) . A novel and fully automated mammographic texture analysis for risk prediction: Results from two case-control studies . Breast Cancer Research vol. 19 , ( 1 )
Smith SG, Foy R, McGowan J, Kobayashi LC, Burn J, Brown K, Side L, Cuzick J ( 2017 ) . General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey . Fam Cancer vol. 16 , ( 4 ) 509 - 516 .
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al. ( 2017 ) . Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al . Ann Oncol
Vasiljevi¿ N, Carter PD, Reuter C, Warman R, Brentnall AR, Carton JR, Cuzick J, Lorincz AT ( 2017 ) . Role of quantitative p16<sup>INK4A</sup> mRNA assay and digital reading of p16<sup>INK4A</sup> immunostained sections in diagnosis of cervical intraepithelial neoplasia . International Journal of Cancer vol. 141 , ( 4 ) 829 - 836 .
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y ( 2017 ) . Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after . JNCI: Journal of the National Cancer Institute
CUZICK JM ( 2017 ) . Preventive Therapy for Cancer . Lancet Oncology, The
Stankiewicz E, Xueying M, Mangham DC, Xu L, Yeste-Velasco M, Fisher G, North B, Chaplin T et al. ( 2017 ) . Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer . Scientific Reports Article 5124 ,
Thorat MA, Cuzick J ( 2017 ) . Preventing invasive breast cancer using endocrine therapy . Breast
Smith SG, Sestak I, Howell A, Forbes J, Cuzick J ( 2017 ) . Participant-reported symptoms and their impact on long-term adherence in the International Breast Cancer Intervention Study (IBIS-1) . Journal of Clinical Oncology vol. 35 , ( 23 )
Cuzick J, Myers O, Lee JH, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM et al. ( 2017 ) . Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing . JAMA Oncology vol. 3 , ( 10 ) 1327 - 1334 .
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M et al. ( 2017 ) . De-escalating and Escalating Treatments for Early Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 . Annals of Oncology vol. 28 , ( 8 ) 1700 - 1712 .
Petersen LK, Restrepo J, Moreira ED, Iversen O-E, Pitisuttithum P, Van Damme P, Joura EA, Olsson S-E et al. ( 2017 ) . Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials . Papillomavirus Res vol. 3 , 105 - 115 .
Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R et al. ( 2017 ) . Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era . JAMA Oncology vol. 3 , ( 6 ) 833 - 837 .
Smith SG, Foy R, McGowan JA, Kobayashi LC, DeCensi A, Brown K, Side L, Cuzick J ( 2017 ) . Prescribing tamoxifen in primary care for the prevention of breast cancer: A national online survey of GPs' attitudes . British Journal of General Practice vol. 67 , ( 659 ) e414 - e427 .
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M et al. ( 2017 ) . Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials . Journal of Clinical Oncology vol. 35 , ( 15 ) 1641 - 1649 .
Lorincz AT, Nathan M, Reuter C, Warman R, THAHA MA, Sheaff M, Vasiljevic N, Ahmad A et al. ( 2017 ) . Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions . Oncotarget vol. 8 , ( 31 ) 50510 - 50520 .
Lorincz AT, Nathan M, Reuter C, Warman R, Thaha MA, Sheaff M, Vasiljevic N, Ahmad A et al. ( 2017 ) . Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions . Oncotarget vol. 8 , ( 31 ) 50510 - 50520 .
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA ( 2017 ) . Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial . TRIALS . Conference: ICTMC/SCT 2017 vol. 18 ,
CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B et al. ( 2017 ) . HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 . European Journal of Cancer
Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel AC, Hajdúch M, Hill C, Walker I et al. ( 2017 ) . Assessing opportunities for coordinated R&amp;D in early cancer detection and management in Europe . International Journal of Cancer vol. 140 , ( 7 ) 1700 - 1701 .
BRENTNALL AR, Sasieni P, Cuzick J ( 2017 ) . Estimating efficacy in trials with selective crossover . Statistics in Medicine
Cuzick J, Forbes JF ( 2017 ) . Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II):an international, double-blind,randomised placebo-controlled trial (vol 383, pg 1041, 2014) . LANCET vol. 389 , ( 10073 ) 1010 - 1010 .
Cuzick J ( 2017 ) . Preventing invasive breast cancer using endocrine therapy . BREAST vol. 32 , S7 - S8 .
CUZICK JM, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J et al. ( 2017 ) . Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population . Cancer Epidemiology, Biomarkers and Prevention
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C et al. ( 2017 ) . Comprehensive comparison of prognostic signatures for breast cancer in TransATAC . CANCER RESEARCH . Conference: San Antonio Breast Cancer Symposium vol. 77 ,
Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M et al. ( 2017 ) . Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC . vol. 77 , Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ ( 2017 ) . Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1) . CANCER RESEARCH . Conference: San Antonio Breast Cancer Symposium vol. 77 ,
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD et al. ( 2017 ) . Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial . CANCER RESEARCH . Conference: San Antonio Breast Cancer Symposium vol. 77 ,
Berney D, Ahmad A, Parameshwaran V, Scardino P, Moller H, Cuzick J, Beltran L ( 2017 ) . Should Reporting of Peri-Neural Invasion and Extra-Capsular Extension Be Mandatory in Prostate Cancer BiopsieS? Correlation with Outcome in 988 Cases Treated Conservatively . MODERN PATHOLOGY . vol. 30 , 214A - 214A .
Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC et al. ( 2017 ) . Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis . Ann Intern Med vol. 166 , ( 2 ) 118 - 127 .
Brentnall AR, Duffy SW, Cuzick J ( 2017 ) . To the editor . vol. 376 , is. 1 ,
Cuzick J ( 2017 ) . Preventive therapy . Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition ,
Nair KP, Harkness EF, Gadde S, Lim YY, Maxwell AJ, Moschidis E, Foden P, Cuzick J et al. ( 2017 ) . The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation . Progress in Biomedical Optics and Imaging - Proceedings of SPIE . vol. 10134 ,
BRENTNALL AR, Cuzick J ( 2016 ) . Use of the concordance index for predictors of censored survival data . Statistical Methods in Medical Research
CUZICK J, BRENTNALL AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I et al. ( 2016 ) . Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials . Journal of Clinical Oncology vol. 35 , ( 7 ) 743 - 750 .
Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM et al. ( 2016 ) . Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region . Papillomavirus Research vol. 2 , 61 - 69 .
Cuzick J, Wheeler C ( 2016 ) . Need for expanded HPV genotyping for cervical screening . Papillomavirus Res vol. 2 , 112 - 115 .
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N et al. ( 2016 ) . Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines . Obstet Gynecol . vol. 128 , 1248 - 1257 .
Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A, FH-risk study Group, Newman WG et al. ( 2016 ) . The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study . Journal of Medical Genetics
Parameshwaran V, North BV, Moller H, Scardino P, Cuzick J, Beltran L, Berney DM ( 2016 ) . The Significance of Reporting Perineural Invasion in 988 Conservatively Treated Prostate Cancer Patients with Long Term Outcome . JOURNAL OF PATHOLOGY . vol. 240 , 21 - 21 .
Timms K, Cuzick J, Neff C, Reid J, Solimeno C, Sangale Z, Pruss D, Gutin A et al. ( 2016 ) . The molecular landscape of genome instability in prostate cancer (PC) . ANNALS OF ONCOLOGY . vol. 27 ,
Cuzick J, Ahmad AS, Austin J, Cadman L, Ho L, Terry G, Kleeman M, Ashdown-Barr L et al. ( 2016 ) . A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4 . Journal of Clinical Virology vol. 82 , Article C , 145 - 151 .
Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P et al. ( 2016 ) . Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico . BMC Infect Dis vol. 16 , 461 - 461 .
McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM ( 2016 ) . Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico . Journal of Rural Health
Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A et al. ( 2016 ) . Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials . Breast Cancer Research and Treatment vol. 158 , ( 3 ) 591 - 596 .
Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A et al. ( 2016 ) . Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials . Pediatrics vol. 138 , ( 2 )
Šestak I, Cuzick J ( 2016 ) . Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors . Expert Rev Endocrinol Metab vol. 11 , ( 5 ) 425 - 432 .
Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J ( 2016 ) . Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors . Breast Cancer Research and Treatment vol. 159 , ( 1 )
Stankiewicz E, Mao X, Mangham DC, Xu L, Fisher G, North B, Moller H, Scardino P et al. ( 2016 ) . Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer . Scientific Reports vol. 7 ,
Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W et al. ( 2016 ) . Performance of a cartridge based assay for the detection of clinically significant HPV infection – lessons from VALGENT (Validation of HPV Genotyping Tests) . Journal of Clinical MicrobiologyJCM.00897-16 - JCM.00897-16 .
Astley S, Harkness E, Sergeant J, Stavrinos P, Warren R, Wilson M, Brentnall A, Cuzick J et al. ( 2016 ) . A comparison of four methods of mammographic density measurement in the UK Predicting Risk Of Cancer At Screening (PROCAS) study - on behalf of the PROCAS Study team . EUROPEAN JOURNAL OF CANCER . vol. 61 , S6 - S6 .
Sasieni PD, Duffy SW, Cuzick J ( 2016 ) . Ovarian cancer screening: UKCTOCS trial . vol. 387 , is. 10038 ,
Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D ( 2016 ) . Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer . Clinical Cancer Research vol. 22 , ( 18 )
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D et al. ( 2016 ) . Re: Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort Editorial Comment . JOURNAL OF UROLOGY vol. 195 , ( 6 ) 1779 - 1780 .
Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J et al. ( 2016 ) . Validation of a DNA methylation HPV triage classifier in a screening sample . International Journal of Cancer vol. 138 , ( 11 ) 2745 - 2751 .
Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM ( 2016 ) . Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 34 ,
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C et al. ( 2016 ) . Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy . Journal of the National Cancer Institute vol. 108 , ( 11 )
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW ( 2016 ) . Impact of screening on breast cancer mortality-response . Cancer Epidemiology Biomarkers and Prevention vol. 25 , ( 5 )
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S et al. ( 2016 ) . Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial . Annals of Oncology vol. 27 , ( 5 ) 806 - 812 .
Evans DGR, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L et al. ( 2016 ) . Breast cancer risk feedback to women in the UK NHS breast screening population . British Journal of Cancer vol. 114 , ( 9 ) 1045 - 1052 .
Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P et al. ( 2016 ) . Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome . British Journal of Cancer vol. 114 , 1068 - 1083 .
Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J et al. ( 2016 ) . Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis . Annals of Oncology vol. 27 , ( 4 ) 575 - 590 .
Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C et al. ( 2016 ) . HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico . Salud Publica Mex vol. 58 , ( 2 ) 211 - 219 .
Bishoff J, Freedland S, Schlomm T, Reid J, Brawer M, Stone S, Cuzick J ( 2016 ) . THE CCP SCORE PROVIDES SIGNIFICANT PROGNOSTIC INFORMATION IN GLEASON SCORE < 7 PATIENTS . JOURNAL OF UROLOGY . vol. 195 , E18 - E18 .
Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P et al. ( 2016 ) . Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study . Salud Publica Mex vol. 58 , ( 2 ) 197 - 210 .
Massat NJ, Sasieni PD, Tataru D, Parmar D, Cuzick J, Duffy SW ( 2016 ) . Explaining the better prognosis of screening-exposed breast cancers: Influence of tumor characteristics and treatment . Cancer Epidemiology Biomarkers and Prevention vol. 25 , ( 3 ) 479 - 487 .
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW ( 2016 ) . Impact of screening on breast cancer mortality: The UK program 20 years on . Cancer Epidemiology Biomarkers and Prevention vol. 25 , ( 3 ) 455 - 462 .
Smith S, Meisel SF, Home R, Cuzick J, Wardle J ( 2016 ) . POISON OR PREVENTION? PATIENT AND CLINICIAN ATTITUDES TOWARDS BREAST CANCER CHEMOPREVENTION . ANNALS OF BEHAVIORAL MEDICINE . vol. 50 , S329 - S329 .
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W et al. ( 2016 ) . Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial . Lancet vol. 387 , ( 10021 ) 866 - 873 .
Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G et al. ( 2016 ) . Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS) . CANCER RESEARCH . vol. 76 ,
Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C et al. ( 2016 ) . EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2-breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS) . CANCER RESEARCH . vol. 76 ,
Smith SG, Sestak I, Forster A, Partridge A, Side L, Horne R, Wardle J, Cuzick J ( 2016 ) . Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis . CANCER RESEARCH . vol. 76 ,
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thurlimann BJK, Seynaeve C et al. ( 2016 ) . HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 . CANCER RESEARCH . vol. 76 ,
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA ( 2016 ) . Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes . CANCER RESEARCH . vol. 76 ,
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA ( 2016 ) . Integration of tumor size and grade with the breast cancer index (BCl) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes . CANCER RESEARCH . vol. 76 ,
Evans DG, Astley SM, Brentnall A, Howell A, Cuzick J ( 2016 ) . Mammographic density and SNPs add to Tyrer-Cuzick and Gail model breast cancer risk in a UK screening cohort . CANCER RESEARCH . vol. 76 ,
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD et al. ( 2016 ) . Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial . CANCER RESEARCH . vol. 76 ,
Zhang Y, Sestak I, Schroeder BE, Dowsett M, Cuzick J, Schnabel CA, Sgroi DC ( 2016 ) . Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study . CANCER RESEARCH . vol. 76 ,
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF et al. ( 2016 ) . Prognostic role and impact of multi -clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial . CANCER RESEARCH . vol. 76 ,
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF et al. ( 2016 ) . Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial . CANCER RESEARCH . vol. 76 ,
Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM et al. ( 2016 ) . Cancer Prevention: Obstacles, Challenges, and the Road Ahead . Journal of the National Cancer Institute vol. 108 , ( 2 )
Cuzick J, Wickerham L, Powles T ( 2016 ) . Differing perspectives on breast cancer chemoprevention . JAMA Oncology vol. 2 , ( 2 ) 276 - 277 .
Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J et al. ( 2016 ) . HPV-FASTER: Broadening the scope for prevention of HPV-related cancer . Nature Reviews Clinical Oncology vol. 13 , ( 2 ) 119 - 132 .
Berney D, Fisher G, North B, Moller H, Scardino P, Cuzick J, Beltran L ( 2016 ) . Validation of Reporting Percentage High Grade Prostate Cancer in 988 Conservatively Treated Patients with Long Term Outcome . MODERN PATHOLOGY . vol. 29 , 217A - 217A .
Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P et al. ( 2016 ) . iPrevent<sup>®</sup>: a tailored, web-based, decision support tool for breast cancer risk assessment and management . Breast Cancer Research and Treatment vol. 156 , ( 1 ) 171 - 182 .
Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J ( 2016 ) . Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends . BMJ Open vol. 6 , ( 1 )
Scardino PT, Cuzick JM, Stone S, Evans B, Jorgensen MR, Eastham JA, Keane TE, Davis JW et al. ( 2016 ) . Application of active surveillance threshold to series of samples submitted for commercial testing . JOURNAL OF CLINICAL ONCOLOGY . vol. 34 ,
Ahmad AS, Vasiljevi¿ N, Carter P, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT ( 2016 ) . A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors . Oncotarget vol. 7 , ( 44 ) 71833 - 71840 .
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE et al. ( 2016 ) . Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: Results from a state-wide surveillance program . Cancer Epidemiology Biomarkers and Prevention vol. 25 , ( 1 ) 36 - 42 .
Phillips KA, Steel EJ, Collins I, Emery J, Pirotta M, Mann GB, Butow P, Hopper JL et al. ( 2016 ) . Transitioning to routine breast cancer risk assessment and management in primary care: What can we learn from cardiovascular disease? . Australian Journal of Primary Health vol. 22 , ( 3 ) 255 - 261 .
Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A ( 2015 ) . PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies . Clinical Oncology vol. 28 , ( 5 ) 317 - 326 .
Brentnall AR, Harkness EF, Astley SM, Donnelly LS, Stavrinos P, Sampson S, Fox L, Sergeant JC et al. ( 2015 ) . Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort . Breast Cancer Research
Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C et al. ( 2015 ) . Performance of the Xpert HPV assay in women attending for cervical screening . Papillomavirus Research vol. 1 , 32 - 37 .
Cuzick J ( 2015 ) . Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer . Ann Oncol vol. 26 , ( 12 ) 2363 - 2366 .
DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J ( 2015 ) . Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake . ecancermedicalscience vol. 9 ,
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J ( 2015 ) . Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial . Journal of Clinical Oncology vol. 34 , ( 2 ) 139 - 143 .
Cuzick J, Sestak I, Thorat MA ( 2015 ) . Impact of preventive therapy on the risk of breast cancer among women with benign breast disease . Breast vol. 24 , S51 - S55 .
Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A et al. ( 2015 ) . Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: A cost-effectiveness analysis . Annals of Internal Medicine vol. 163 , ( 8 ) 589 - 597 .
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al. ( 2015 ) . Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials . The Lancet vol. 386 , ( 10001 ) 1353 - 1361 .
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J et al. ( 2015 ) . Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials . The Lancet vol. 386 , ( 10001 ) 1341 - 1352 .
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O et al. ( 2015 ) . Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial . Cancer Prev Res (Phila) vol. 8 , ( 10 ) 888 - 894 .
Paleari L, Puntoni M, Clavarezza M, Corradengo D, Campazzi E, Caviglia S, Provinciali N, Cuzick J et al. ( 2015 ) . PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies . ANNALS OF ONCOLOGY vol. 26 , 36 - 36 .
Reid JL, Wright TC, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D, Giachetti C ( 2015 ) . Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study . Am J Clin Pathol vol. 144 , ( 3 ) 473 - 483 .
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P et al. ( 2015 ) . Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype . Ann Oncol vol. 26 , ( 8 ) 1685 - 1691 .
Haviland JS, Bliss JM, Bentzen SM, Cuzick J ( 2015 ) . In Regard to Vaidya et al . Int J Radiat Oncol Biol Phys vol. 92 , ( 5 ) 954 - 955 .
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D et al. ( 2015 ) . Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort . British Journal of Cancer vol. 113 , ( 3 ) 382 - 389 .
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y et al. ( 2015 ) . A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women . OBSTETRICAL & GYNECOLOGICAL SURVEY vol. 70 , ( 7 ) 446 - 448 .
Trinh T, Christensen SE, Brand JS, Cuzick J, Czene K, Sjölander A, Bälter K, Hall P ( 2015 ) . Background risk of breast cancer influences the association between alcohol consumption and mammographic density . Br J Cancer vol. 113 , ( 1 ) 159 - 165 .
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A et al. ( 2015 ) . Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer . Clin Cancer Res vol. 21 , ( 12 ) 2763 - 2770 .
Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M et al. ( 2015 ) . Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management . Int J Cancer vol. 136 , ( 12 ) 2854 - 2863 .
Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D et al. ( 2015 ) . Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial . Breast Cancer Res Treat vol. 151 , ( 2 ) 309 - 318 .
Zhang Y, Sestak I, Cuzick JM, Dowsett M, Schnabel CA, Sgroi D ( 2015 ) . Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, Greenberg D, Moller H et al. ( 2015 ) . Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF ( 2015 ) . 16 year long-term follow-up of the IBIS-I breast cancer prevention trial . CANCER RESEARCH . vol. 75 ,
Sestak I, Zhang Y, Schroeder BE, Goss PE, Dowsett M, Sgroi DC, Schnabel CA, Cuzick J ( 2015 ) . Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER plus breast cancer . CANCER RESEARCH . vol. 75 ,
Guerrieri-Gonzaga A, Macis D, Gandini S, Aristarco V, Johansson H, Bollani G, Roth T, Sandri M-T et al. ( 2015 ) . Low serum adiponectin level is an independent risk factor of DCIS in postmenopausal women at increased risk of breast cancer . CANCER RESEARCH . vol. 75 ,
Hiscox S, Smith C, Nicholson RI, Gee J, Harris A, Bliss J, Kalaizak E, Sestak I et al. ( 2015 ) . Nuclear beta-catenin negativity predicts for late relapse in ER plus , tamoxifen-treated breast cancer . CANCER RESEARCH . vol. 75 ,
Howell A, Astley S, Harkness E, Wiseman J, Fox J, Stavrinos P, Wilson M, Lim Y et al. ( 2015 ) . Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs . CANCER RESEARCH . vol. 75 ,
Sestak I, Howell A, Forbes JF, Neven P, Cuzick J ( 2015 ) . Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis . CANCER RESEARCH . vol. 75 ,
Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, Overvad K, Tjønneland A ( 2015 ) . Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark . Int J Cancer vol. 136 , ( 8 ) 1940 - 1947 .
Cuzick J ( 2015 ) . Radiotherapy for breast cancer, the TARGIT-A trial (vol 383, pg 1716, 2014) . LANCET vol. 385 , ( 9976 ) 1396 - 1396 .
Trinh T, Eriksson M, Darabi H, Bonn SE, Brand JS, Cuzick J, Czene K, Sjölander A et al. ( 2015 ) . Background risk of breast cancer and the association between physical activity and mammographic density . Breast Cancer Res vol. 17 ,
Cuzick J, Stone S, Reid J, Fisher G, Moller H, Brawer M, Scardino P, Shore N ( 2015 ) . PATIENT AUA RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE . JOURNAL OF UROLOGY . vol. 193 , E3 - E3 .
Cuzick J, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D et al. ( 2015 ) . VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER . JOURNAL OF UROLOGY . vol. 193 , E4 - E4 .
Brentnall AR, Cuzick J ( 2015 ) . Atypical Hyperplasia of the Breast . NEW ENGLAND JOURNAL OF MEDICINE vol. 372 , ( 13 ) 1269 - 1270 .
Brentnall AR, Cuzick J ( 2015 ) . Atypical hyperplasia of the breast . New England Journal of Medicine vol. 372 , ( 13 ) 1269 - 1272 .
Louvanto K, Franco EL, Ramanakumar AV, Vasiljevi¿ N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F et al. ( 2015 ) . Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16 . Int J Cancer vol. 136 , ( 6 ) E638 - E645 .
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S et al. ( 2015 ) . Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score . J Clin Oncol vol. 33 , ( 8 ) 916 - 922 .
Kylstra JW, Kalnoski M, Quay S, Chen S, Vo T, Cuzick J ( 2015 ) . Nipple aspirate fluid (NAF) cytology in the IBIS-model prediction of breast cancer (BCA) risk . BREAST vol. 24 , S68 - S69 .
Cuzick J, Thorat M ( 2015 ) . Preventing invasive breast cancer in women at high risk based on benign/in situ pathology . BREAST . vol. 24 , S11 - S11 .
Stone S, Cuzick JM, Fisher G, Yang ZH, North B, Berney DM, Beltran L, Greenberg D et al. ( 2015 ) . Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y et al. ( 2015 ) . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women . N Engl J Med vol. 372 , ( 8 ) 711 - 723 .
Brentnall AR, Cuzick J, Field J, Duffy SW ( 2015 ) . A concordance index for matched case-control studies with applications in cancer risk . Stat Med vol. 34 , ( 3 ) 396 - 405 .
Castle PE, Cuzick J, Stoler MH, Wright TC, Reid JL, Dockter J, Giachetti C, Getman D ( 2015 ) . Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study . Am J Clin Pathol vol. 143 , ( 2 ) 160 - 167 .
Beltran L, North B, Fisher G, Moller H, Scardino P, Cuzick J, Berney D ( 2015 ) . Long Term Outcome in a Biopsy Cohort of 988 Conservatively Treated Prostate Cancers. Evidence for Revised Gleason Grading and Use of the Worst Scoring Core . LABORATORY INVESTIGATION . vol. 95 , 207A - 208A .
Sestak I, Cuzick J ( 2015 ) . Update on breast cancer risk prediction and prevention . Curr Opin Obstet Gynecol vol. 27 , ( 1 ) 92 - 97 .
Almonte M, Ferreccio C, Luciani S, Gonzales M, Delgado JM, Santos C, Alvarez M, Cuzick J et al. ( 2015 ) . Visual Inspection after Acetic Acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru . PLoS ONE vol. 10 , ( 1 )
Sestak I, Cuzick J ( 2015 ) . Markers for the identification of late breast cancer recurrence . Breast Cancer Res vol. 17 ,
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ et al. ( 2015 ) . Estimates of benefits and harms of prophylactic use of aspirin in the general population . Ann Oncol vol. 26 , ( 1 ) 47 - 57 .
Cuzick J ( 2015 ) . Gardasil 9 joins the fight against cervix cancer . Expert Rev Vaccines vol. 14 , ( 8 ) 1047 - 1049 .
Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, Lorincz AT ( 2015 ) . HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier . Cancer Biomarkers vol. 15 , ( 5 ) 669 - 675 .
Cuzick J, Thorat MA ( 2015 ) . PSA testing for prostate cancer screening - Authors' reply . The Lancet Oncology vol. 16 , ( 1 )
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators ( 2015 ) . Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial . Lancet Oncol vol. 16 , ( 1 ) 67 - 75 .
Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM, Kinney W, Waxman A et al. ( 2015 ) . The interpretive variability of cervical biopsies and its relationship to HPV status . American Journal of Surgical Pathology vol. 39 , ( 6 ) 729 - 736 .
Sestak I, Singh S, Cuzick J ( 2014 ) . Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, doubleblind, randomised, placebo-controlled trial (vol 15, pg 1464, 2014) . LANCET ONCOLOGY vol. 15 , ( 13 ) E587 - E587 .
Yang Z, Cuzick J, Hunt WC, Wheeler CM ( 2014 ) . Concurrence of multiple human papillomavirus infections in a large US population-based cohort . Am J Epidemiol vol. 180 , ( 11 ) 1066 - 1075 .
Cuzick J ( 2014 ) . Endpoints for the evaluation of breast cancer treatments . J Natl Cancer Inst vol. 106 , ( 12 )
Thorat MA, Cuzick J ( 2014 ) . Reply to the Letter to the Editor "The harms of low-dose aspirin prophylaxis are overstated" by P. Elwood and G. Morgan . Annals of Oncology
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M et al. ( 2014 ) . Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial . Lancet Oncology vol. 15 , ( 13 ) 1460 - 1468 .
Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC et al. ( 2014 ) . The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management . Cancer Cytopathol vol. 122 , ( 11 ) 842 - 850 .
Warwick J, Birke H, Stone J, Warren RML, Pinney E, Brentnall AR, Duffy SW, Howell A et al. ( 2014 ) . Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I . Breast Cancer Res vol. 16 , ( 5 )
Collins IM, Steel E, Mann GB, Emery JD, Bickerstaffe A, Trainer A, Butow P, Pirotta M et al. ( 2014 ) . Assessing and managing breast cancer risk: clinicians' current practice and future needs . Breast vol. 23 , ( 5 ) 644 - 650 .
Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR et al. ( 2014 ) . Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease . Cancer Epidemiol Biomarkers Prev vol. 23 , ( 10 ) 1997 - 2008 .
Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley S, Wilson M et al. ( 2014 ) . Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention . Cancer Prev Res (Phila) vol. 7 , ( 10 ) 993 - 1001 .
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG et al. ( 2014 ) . Prevention and early detection of prostate cancer . Lancet Oncol vol. 15 , ( 11 ) e484 - e492 .
Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J, Lorincz AT ( 2014 ) . A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes . Int J Cancer vol. 135 , ( 6 ) 1425 - 1432 .
Vasiljevi¿ N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J et al. ( 2014 ) . DNA methylation gene-based models indicating independent poor outcome in prostate cancer . BMC Cancer vol. 14 ,
Cuzick J ( 2014 ) . Editorial comment . J Urol vol. 192 , ( 2 )
Cuzick J ( 2014 ) . Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy EDITORIAL COMMENT . JOURNAL OF UROLOGY vol. 192 , ( 2 ) 414 - 414 .
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, New Mexico HPV Pap Registry Steering Committee ( 2014 ) . The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States . Int J Cancer vol. 135 , ( 3 ) 624 - 634 .
Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Seccombe M, Boyle F, Reaby L et al. ( 2014 ) . Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial . Br J Cancer vol. 111 , ( 1 ) 1 - 7 .
Cuzick J ( 2014 ) . Progress in breast cancer prevention . EUROPEAN JOURNAL OF CANCER vol. 50 , S7 - S7 .
Sestak I, Zhang Y, Schnabel CA, Schroeder B, Ander ME, Goss PE, Cuzick JM, Dowsett M et al. ( 2014 ) . Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,
Forbes JF, Dowsett M, Bradley R, Ingle JN, Aihara T, Bliss JM, Boccardo FM, Coates AS et al. ( 2014 ) . Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam) . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,
Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N et al. ( 2014 ) . Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,
Cuzick JM, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D et al. ( 2014 ) . Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,
Cuzick J ( 2014 ) . Radiotherapy for breast cancer, the TARGIT-A trial . Lancet vol. 383 , ( 9930 )
Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, Benard VB, Wheeler CM et al. ( 2014 ) . A population-based evaluation of cervical screening in the United States: 2008-2011 . Cancer Epidemiol Biomarkers Prev vol. 23 , ( 5 ) 765 - 773 .
Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L et al. ( 2014 ) . Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions . J Clin Virol vol. 60 , ( 1 ) 44 - 49 .
Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, Stavrinos P et al. ( 2014 ) . Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic . Br J Cancer vol. 110 , ( 7 ) 1681 - 1687 .
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. ( 2014 ) . EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II) . OSTEOPOROSIS INTERNATIONAL . vol. 25 , S281 - S281 .
Cuzick J, Stone S, Yang ZH, Reid J, Fisher G, Berney D, Beltran L, Moller H et al. ( 2014 ) . VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT . JOURNAL OF UROLOGY . vol. 191 , E936 - E936 .
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al. ( 2014 ) . Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial . Lancet vol. 383 , ( 9922 ) 1041 - 1048 .
Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G et al. ( 2014 ) . Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer . Br J Cancer vol. 110 , ( 6 ) 1655 - 1662 .
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A ( 2014 ) . A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers . J Clin Virol vol. 59 , ( 3 ) 161 - 166 .
Evans G, Stavrinos P, Dawe S, Harvie M, Wilson M, Maxwell A, Brentnall A, Cuzick J et al. ( 2014 ) . Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: First prospective results from PROCAS . EUROPEAN JOURNAL OF CANCER . vol. 50 , S3 - S4 .
Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM, New Mexico HPV Pap Registry Steering Committee ( 2014 ) . Cervical excisional treatment of young women: a population-based study . Gynecol Oncol vol. 132 , ( 3 ) 628 - 635 .
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT ( 2014 ) . Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women . Gynecol Oncol vol. 132 , ( 3 ) 709 - 714 .
Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J, Bonde J ( 2014 ) . Inter and intra laboratory reproducibility of BD Onclarity HPV assay in ThinPrep primarily screening samples . APMIS . vol. 122 , 30 - 30 .
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Cuzick J ( 2014 ) . Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2-breast cancer . EUROPEAN JOURNAL OF CANCER . vol. 50 , S105 - S106 .
Cuzick J ( 2014 ) . The prevention of breast cancer . EUROPEAN JOURNAL OF CANCER . vol. 50 , S34 - S35 .
Brentnall AR, Evans DG, Cuzick J ( 2014 ) . Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK . Br J Cancer vol. 110 , ( 3 ) 827 - 828 .
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N et al. ( 2014 ) . Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials . The Lancet vol. 383 , ( 9916 ) 524 - 532 .
Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF et al. ( 2014 ) . Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 29 , S110 - S110 .
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA et al. ( 2014 ) . Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence . Clin Cancer Res vol. 20 , ( 2 ) 344 - 357 .
Castañón A, Landy R, Cuzick J, Sasieni P ( 2014 ) . Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study . PLoS Med vol. 11 , ( 1 )
Vasiljevi¿ N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT ( 2014 ) . DNA methylation of PITX2 predicts poor survival in men with prostate cancer . Biomark Med vol. 8 , ( 9 ) 1143 - 1150 .
McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G et al. ( 2014 ) . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials . The Lancet vol. 383 , ( 9935 ) 2127 - 2135 .
Cuzick J, Thorat MA ( 2014 ) . Preface .
Cuzick J ( 2014 ) . Prognostic value of a cell cycle progression score for men with prostate cancer . Recent Results Cancer Res vol. 202 , 133 - 140 .
Thorat M, Cuzick J ( 2014 ) . Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population . European Journal of Epidemiology vol. 30 , ( 1 ) 5 - 18 .
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M et al. ( 2013 ) . Comprehensive control of human papillomavirus infections and related diseases . Vaccine vol. 31 , H1 - H31 .
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al. ( 2013 ) . Comprehensive control of human papillomavirus infections and related diseases . Vaccine vol. 31 Suppl 6 , G1 - 31 .
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al. ( 2013 ) . Comprehensive control of human papillomavirus infections and related diseases . Vaccine vol. 31 Suppl 5 , F1 - 31 .
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al. ( 2013 ) . Breast cancer prevention using anastrozole in postmenopausal women at high risk . CANCER RESEARCH . vol. 73 ,
Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsky P, Cowens W, Ferree S, Schaper C et al. ( 2013 ) . Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score . CANCER RESEARCH vol. 73 ,
Cuzick J ( 2013 ) . Duration of Aromatase Inhibitor Treatment in Breast Cancer: The Role of the 'Carryover Effect' . ONCOLOGY-NEW YORK vol. 27 , ( 12 ) 1224 - 1225 .
Thorat MA, Cuzick J ( 2013 ) . Role of aspirin in cancer prevention . Curr Oncol Rep vol. 15 , ( 6 ) 533 - 540 .
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M et al. ( 2013 ) . Comprehensive Control of Human Papillomavirus Infections and Related Diseases . Vaccine vol. 31 , ( SUPPL.8 ) 11 - 131 .
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al. ( 2013 ) . Comprehensive control of human papillomavirus infections and related diseases . Vaccine vol. 31 Suppl 8 , I1 - 31 .
Cuzick J, Yang Z ( 2013 ) . A frailty model for interaction between multiple events . JOURNAL OF MULTIVARIATE ANALYSIS vol. 122 , 133 - 147 .
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J ( 2013 ) . Factors predicting late recurrence for estrogen receptor-positive breast cancer . J Natl Cancer Inst vol. 105 , ( 19 ) 1504 - 1511 .
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A et al. ( 2013 ) . Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population . Lancet Oncol vol. 14 , ( 11 ) 1067 - 1076 .
Collins IM, Keogh LA, Steel E, Emery J, Pirotta M, Mann B, Butow P, Trainer A et al. ( 2013 ) . Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease? . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Cuzick J ( 2013 ) . Should all men receive PSA screening? . EUROPEAN JOURNAL OF CANCER . vol. 49 , S20 - S20 .
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A et al. ( 2013 ) . Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline . J Clin Oncol vol. 31 , ( 23 ) 2942 - 2962 .
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J et al. ( 2013 ) . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy . J Clin Oncol vol. 31 , ( 22 ) 2783 - 2790 .
Lorincz AT, Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A et al. ( 2013 ) . HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology . Int J Cancer vol. 133 , ( 3 ) 637 - 644 .
Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J ( 2013 ) . Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study . Breast Cancer Res Treat vol. 140 , ( 2 ) 253 - 262 .
Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S et al. ( 2013 ) . Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer . Br J Cancer vol. 108 , ( 12 ) 2582 - 2589 .
Mesher D, Szarewski A, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Young M et al. ( 2013 ) . Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities . Eur J Cancer vol. 49 , ( 9 ) 2179 - 2186 .
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF et al. ( 2013 ) . Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data . Lancet vol. 381 , ( 9880 ) 1827 - 1834 .
Pugliano L, Zardavas D, Paesmans M, Sestak I, Gelber RD, Cuzick JM, Dowsett M, Awada A et al. ( 2013 ) . A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER plus BC? . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Phillips K-A, Keogh LA, Steel E, Collins IM, Emery J, Pirotta M, Mann B, Butow P et al. ( 2013 ) . Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease? . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Collins IM, Keogh LA, Steel E, Mann B, Emery J, Pirotta M, Moreton J, Butow P et al. ( 2013 ) . Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want? . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO et al. ( 2013 ) . Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR plus early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Brawer MK, Cuzick JM, Cooperberg MR, Swanson GP, Freedland SJ, Reid JE, Fisher G, Lanchbury JS et al. ( 2013 ) . Prolaris: A novel genetic test for prostate cancer prognosis . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S et al. ( 2013 ) . Comparing the performance of six human papillomavirus tests in a screening population . Br J Cancer vol. 108 , ( 4 ) 908 - 913 .
Vasiljevi¿ N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Møller H, Yu Y et al. ( 2013 ) . Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer . Prostate Cancer Prostatic Dis vol. 16 , ( 1 ) 35 - 40 .
Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, Athena HPV Study Group ( 2013 ) . Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study . Am J Obstet Gynecol vol. 208 , ( 3 ) 184.e1 - 184.e11 .
Brawer MK, Cooperberg MR, Freedland SJ, Swanson GP, Stone S, Reid JE, Gutin A, Carroll P et al. ( 2013 ) . Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Cuzick J, Thomas Cox J, Zhang G, Einstein MH, Stoler M, Trupin S, Behrens CM ( 2013 ) . Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions . Int J Cancer vol. 132 , ( 4 ) 959 - 966 .
Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM, Transatlantic Prostate Group ( 2013 ) . Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort . Br J Cancer vol. 108 , ( 2 ) 271 - 277 .
Stoler MH, Wright TC, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C ( 2013 ) . APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results . Am J Obstet Gynecol vol. 208 , ( 2 ) 144.e1 - 144.e8 .
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. ( 2013 ) . Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II) . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 28 ,
Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S et al. ( 2013 ) . Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial . Lancet Oncol vol. 14 , ( 2 ) 168 - 176 .
Ahmad I, Singh LB, Yang ZH, Kalna G, Fleming J, Fisher G, Cooper C, Cuzick J et al. ( 2013 ) . Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer . Br J Cancer vol. 108 , ( 1 ) 149 - 154 .
Palva T, Ranta H, Koivisto A-M, Pylkkänen L, Cuzick J, Holli K ( 2013 ) . A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial . Eur J Cancer vol. 49 , ( 1 ) 45 - 51 .
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA et al. ( 2013 ) . A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination . Int J Cancer vol. 132 , ( 1 ) 198 - 207 .
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S et al. ( 2013 ) . European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication . ENDOSCOPY vol. 45 , ( 1 ) 51 - 59 .
Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S et al. ( 2013 ) . The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy . Int J Cancer vol. 132 , ( 1 ) 101 - 108 .
Sainsbury R, Loddo M, Proctor I, Stoeber K, Williams G, Thorat M, Cuzick J ( 2012 ) . Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of 'intermediate grade' disease and gives clinically meanignful information . CANCER RESEARCH . vol. 72 ,
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M ( 2012 ) . Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study . CANCER RESEARCH vol. 72 ,
Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M ( 2012 ) . Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study . CANCER RESEARCH vol. 72 ,
Motion J, Ashcroft L, Dowsett M, Cuzick J, Hickman J, Evans G, Eccles D, Eeles R et al. ( 2012 ) . The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer . CANCER RESEARCH vol. 72 ,
Sestak I, Cuzick J ( 2012 ) . Preventive therapy for breast cancer . Curr Oncol Rep vol. 14 , ( 6 ) 568 - 573 .
Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, J L M Meijer C, Sankaranarayanan R et al. ( 2012 ) . New technologies and procedures for cervical cancer screening . Vaccine vol. 30 Suppl 5 , F107 - F116 .
Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M ( 2012 ) . Nucleic acid tests for the detection of alpha human papillomaviruses . Vaccine vol. 30 Suppl 5 , F100 - F106 .
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M ( 2012 ) . CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients (vol 104, pg 452, 2012) . JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104 , ( 22 ) 1772 - 1772 .
Cuzick J ( 2012 ) . HPV ELIMINATION OF CERVICAL CANCER: THE NOVEL OPTIONS IN VACCINATION AND SCREENING . ANNALS OF ONCOLOGY . vol. 23 , 53 - 53 .
Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M ( 2012 ) . PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT . ANNALS OF ONCOLOGY . vol. 23 , 75 - 76 .
Cuzick J ( 2012 ) . Breast density predicts endocrine treatment outcome in the adjuvant setting . Breast Cancer Res vol. 14 , ( 4 )
Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM et al. ( 2012 ) . Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer . Virchows Arch vol. 461 , ( 2 ) 103 - 107 .
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M ( 2012 ) . Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response . JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104 , ( 16 ) 1267 - 1268 .
Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J ( 2012 ) . Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial . Br J Cancer vol. 107 , ( 2 ) 230 - 233 .
Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B et al. ( 2012 ) . Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention . Cancer Prev Res (Phila) vol. 5 , ( 7 ) 943 - 951 .
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J ( 2012 ) . Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer . Breast Cancer Res Treat vol. 134 , ( 2 ) 727 - 734 .
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C ( 2012 ) . Aspirin and cancer risk: a quantitative review to 2011 . Ann Oncol vol. 23 , ( 6 ) 1403 - 1415 .
Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S et al. ( 2012 ) . Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study . J Clin Microbiol vol. 50 , ( 6 ) 1867 - 1873 .
Stankiewicz E, Ng M, Cuzick J, Mesher D, Watkin N, Lam W, Corbishley C, Berney DM ( 2012 ) . The prognostic value of Ki-67 expression in penile squamous cell carcinoma . J Clin Pathol vol. 65 , ( 6 ) 534 - 537 .
Howell A, Cuzick J ( 2012 ) . Oestrogen and breast cancer: results from the WHI trial . Lancet Oncol vol. 13 , ( 5 ) 437 - 438 .
Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M et al. ( 2012 ) . [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors] . Epidemiol Prev vol. 36 , ( 3-4 Suppl 1 ) e1 - 72 .
Ronco G, Meijer CJL, Cuzick J, Giorgi-Rossi P, Peto J, Segnan N, Dillner J ( 2012 ) . Screening for cervical cancer . Ann Intern Med vol. 156 , ( 8 ) 604 - 605 .
Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M et al. ( 2012 ) . Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study . Breast Cancer Res vol. 14 , ( 2 )
Allawi Z, Cuzick J, Baum M, ATAC/LATTE investigators ( 2012 ) . Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates? . Ann Oncol vol. 23 , ( 4 ) 866 - 869 .
Singh S, Cuzick J, Mesher D, Richmond B, Howell A ( 2012 ) . Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole . Breast Cancer Res Treat vol. 132 , ( 2 ) 625 - 629 .
Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B et al. ( 2012 ) . Prevention of breast cancer in the context of a national breast screening programme . J Intern Med vol. 271 , ( 4 ) 321 - 330 .
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I et al. ( 2012 ) . CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients . J Natl Cancer Inst vol. 104 , ( 6 ) 452 - 460 .
Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I et al. ( 2012 ) . ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer . Breast Cancer Res vol. 14 , ( 2 )
Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J et al. ( 2012 ) . Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort . Br J Cancer vol. 106 , ( 6 ) 1095 - 1099 .
Cuzick J ( 2012 ) . The Role of HPV Testing in Cervical Screening . JOURNAL OF PATHOLOGY . vol. 226 , S2 - S2 .
Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, Buyse M, Cameron D et al. ( 2012 ) . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials . LANCET vol. 379 , ( 9814 ) 432 - 444 .
Jeetle SS, Yang ZH, Stankiewicz E, Fisher G, Cooper C, Foster CS, Moller H, Scardino P et al. ( 2012 ) . Androgen Receptor in Tumor and Stroma in Conservatively Treated Prostate Cancer . LABORATORY INVESTIGATION . vol. 92 , 215A - 215A .
Stone SM, Cuzick J, Reid JE, Mesher D, Berney DM, Moller H, Speights VO, Fisher G et al. ( 2012 ) . Cell cycle progression genes differentiate indolent from aggressive prostate cancer . EUROPEAN UROLOGY SUPPLEMENTS vol. 11 , ( 1 ) E430 - U942 .
Berney D, Fisher G, Yang ZH, Moller H, Kudahetti S, Foster C, Reuter V, Scardino P et al. ( 2012 ) . Molecular Factors Showing Multivariate Significance for Outcome in a Conservatively Treated Prostate Cancer Biopsy Cohort . MODERN PATHOLOGY . vol. 25 , 192A - 192A .
Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S et al. ( 2012 ) . Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011 . Ecancermedicalscience vol. 6 ,
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, Kenter GG, Cuzick J et al. ( 2012 ) . Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial . Lancet Oncol vol. 13 , ( 1 ) 78 - 88 .
Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevi¿ N, Scibior-Bentkowska D, Wu K, Ahmad AS et al. ( 2012 ) . Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes . Cancer Biomark vol. 11 , ( 2-3 ) 75 - 88 .
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, Ferree S, Storhoff J, Schaper C et al. ( 2011 ) . Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study . CANCER RESEARCH . vol. 71 ,
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-Knowles E, Salter J et al. ( 2011 ) . Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial . CANCER RESEARCH vol. 71 ,
Evans DGR, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Wilson M et al. ( 2011 ) . Feasibility and Acceptability of Offering Breast Cancer Risk Estimation in the Context of the UK National Health Service Breast Cancer Screening Programme: A New Paradigm for Cancer Prevention . CANCER RESEARCH vol. 71 ,
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar A, Forbes JF, Cuzick J ( 2011 ) . Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study . CANCER RESEARCH . vol. 71 ,
Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A et al. ( 2011 ) . Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study . CANCER RESEARCH vol. 71 ,
Assi V, Warwick J, Cuzick J, Duffy SW ( 2011 ) . Clinical and epidemiological issues in mammographic density . Nat Rev Clin Oncol vol. 9 , ( 1 ) 33 - 40 .
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M et al. ( 2011 ) . Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males (vol 83, pg 1744, 2011) . J MED VIROL vol. 83 , ( 12 ) 2237 - 2237 .
Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, Robles SC, Winkler JL et al. ( 2011 ) . Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru . Int J Gynecol Cancer vol. 21 , ( 9 ) 1654 - 1663 .
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S et al. ( 2011 ) . Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors . J Clin Oncol vol. 29 , ( 33 ) 4365 - 4372 .
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL et al. ( 2011 ) . Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group . J Natl Cancer Inst vol. 103 , ( 22 ) 1656 - 1664 .
Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J ( 2011 ) . Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial . J Clin Oncol vol. 29 , ( 32 ) 4266 - 4272 .
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E et al. ( 2011 ) . Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer . J Clin Oncol vol. 29 , ( 32 ) 4273 - 4278 .
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C et al. ( 2011 ) . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials . The Lancet vol. 378 , ( 9804 ) 1707 - 1716 .
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M et al. ( 2011 ) . Human Papillomavirus Genotype Detection and Viral Load in Paired Genital and Urine Samples From Both Females and Males . J MED VIROL vol. 83 , ( 10 ) 1744 - 1751 .
Almonte M, Sasieni P, Cuzick J ( 2011 ) . Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines . Best Pract Res Clin Obstet Gynaecol vol. 25 , ( 5 ) 617 - 629 .
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM ( 2011 ) . Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 27 )
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM ( 2011 ) . Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it . J Clin Oncol vol. 29 , ( 27_suppl )
Cuzick J ( 2011 ) . Cervix Cancer Vaccination . EUROPEAN JOURNAL OF CANCER . vol. 47 , S15 - S15 .
Evans G, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M et al. ( 2011 ) . Feasibility and acceptability of offering breast cancer risk estimation in the context of the UK National Health Service Breast Cancer Screening Programme: a new paradigm for cancer prevention . JOURNAL OF MEDICAL GENETICS . vol. 48 , S41 - S41 .
Cuzick J, Glasier A, La Vecchia C, Maraganore DM, Negri E, Rossi M, Spector T, Trichopoulos D et al. ( 2011 ) . Perimenopausal risk factors and future health . HUM REPROD UPDATE vol. 17 , ( 5 ) 706 - 717 .
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al. ( 2011 ) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials . The Lancet vol. 378 , ( 9793 ) 771 - 784 .
Jeetle S, Yang ZH, Stankiewicz E, Fisher G, Cuzick J, Berney D ( 2011 ) . Long-term outcome and neuroendocrine differentiation in conservatively treated prostate cancers . VIRCHOWS ARCH vol. 459 , S59 - S59 .
Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S et al. ( 2011 ) . Predictive algorithms for adjuvant therapy: TransATAC . Steroids vol. 76 , ( 8 ) 777 - 780 .
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Reid JE, Gutin A, Lanchbury JS et al. ( 2011 ) . Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )
Cuzick JM, Fisher G, Berney D, Mesher D, Møller H, Reid JE, Gutin A, Lanchbury JS et al. ( 2011 ) . Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort . J Clin Oncol vol. 29 , ( 15_suppl )
O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G et al. ( 2011 ) . Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively . Int J Cancer vol. 128 , ( 10 ) 2373 - 2381 .
Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RML ( 2011 ) . Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study . J Natl Cancer Inst vol. 103 , ( 9 ) 744 - 752 .
Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A et al. ( 2011 ) . Preventive therapy for breast cancer: a consensus statement . Lancet Oncol vol. 12 , ( 5 ) 496 - 503 .
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA et al. ( 2011 ) . The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women . Int J Obes (Lond) vol. 35 , ( 5 ) 714 - 727 .
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE ( 2011 ) . Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial . Ann Oncol vol. 22 , ( 4 ) 857 - 862 .
Stankiewicz E, Prowse DM, Ng M, Cuzick J, Mesher D, Hiscock F, Lu Y-J, Watkin N et al. ( 2011 ) . Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas . PLoS One vol. 6 , ( 3 )
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators ( 2011 ) . 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply . Lancet Oncol vol. 12 , ( 3 )
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators ( 2011 ) . 10-year analysis of the ATAC trial: wrong conclusion? Reply . LANCET ONCOL vol. 12 , ( 3 ) 217 - 217 .
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO et al. ( 2011 ) . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study . Lancet Oncol vol. 12 , ( 3 ) 245 - 255 .
Stankiewicz E, Mesher D, Ng M, Cuzick J, Prowse D, Hiscock F, Lu YJ, Lam W et al. ( 2011 ) . Alternative Pathways of Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas . MODERN PATHOLOGY . vol. 24 , 225A - 226A .
Stankiewicz E, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Kudahetti S, Watkin N et al. ( 2011 ) . The retinoblastoma protein/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma . Histopathology vol. 58 , ( 3 ) 433 - 439 .
Vasiljevi¿ N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L et al. ( 2011 ) . Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing . Dis Markers vol. 30 , ( 4 ) 151 - 161 .
Rajab R, Fisher G, Kattan MW, Foster CS, Møller H, Oliver T, Reuter V, Scardino PT et al. ( 2011 ) . An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent . Mod Pathol vol. 24 , ( 1 ) 58 - 63 .
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H et al. ( 2011 ) . Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial . Lancet Oncol vol. 12 , ( 1 ) 21 - 29 .
Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, Coleman R, Howell A et al. ( 2011 ) . One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study . BONE . vol. 48 , S24 - S24 .
Cuzick J ( 2010 ) . Breast cancer prevention in the developing world . Breast Cancer Res vol. 12 Suppl 4 ,
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S et al. ( 2010 ) . Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial . CANCER RESEARCH . vol. 70 ,
Ring AE, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J ( 2010 ) . The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial . CANCER RESEARCH . vol. 70 ,
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators ( 2010 ) . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial . LANCET ONCOL vol. 11 , ( 12 ) 1135 - 1141 .
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators ( 2010 ) . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial . Lancet Oncol vol. 11 , ( 12 ) 1135 - 1141 .
Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW ( 2010 ) . Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam) . Int J Cancer vol. 127 , ( 11 ) 2639 - 2644 .
Duffy SW, Mackay J, Thomas S, Anderson E, Evans DG, Fielder H, Fox R, Gray J et al. ( 2010 ) . Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study . LANCET ONCOL vol. 11 , ( 12 ) 1127 - 1134 .
Rajab R, Fisher G, Kattan MW, Foster CS, Oliver T, Møller H, Reuter V, Scardino P et al. ( 2010 ) . Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort . Virchows Arch vol. 457 , ( 5 ) 547 - 553 .
Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M et al. ( 2010 ) . Significant differences in UK and US female bone density reference ranges . Osteoporos Int vol. 21 , ( 11 ) 1871 - 1880 .
Dowsett M, Pineda S, Cuzick J ( 2010 ) . What Is the Value of the 21 Gene Recurrence Score in HER2-Negative Patients? Reply . J CLIN ONCOL vol. 28 , ( 31 ) E648 - E648 .
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Lanchbury J, Gutin A, Stone S ( 2010 ) . PROGNOSTIC VALUE OF A CELL CYCLE EXPRESSION PROFILE SCORE AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE CANCER . ANNALS OF ONCOLOGY . vol. 21 , 63 - 63 .
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J ( 2010 ) . Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial . J Clin Oncol vol. 28 , ( 21 ) 3411 - 3415 .
Cuzick J ( 2010 ) . Tamoxifen and the factor V Leiden mutation . J Natl Cancer Inst vol. 102 , ( 13 ) 918 - 919 .
Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R et al. ( 2010 ) . Performance of the Abbott RealTime High-Risk HPV Test in Women With Abnormal Cervical Cytology Smears . J MED VIROL vol. 82 , ( 7 ) 1186 - 1191 .
Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, Fentiman IS, George WD et al. ( 2010 ) . A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial . Br J Cancer vol. 103 , ( 1 ) 94 - 100 .
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin ( 2010 ) . Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial (vol 359, pg 1291, 2002) . LANCET vol. 375 , ( 9732 ) 2142 - 2142 .
Cuzick J ( 2010 ) . Long-term follow-up in cancer prevention trials (It ain't over 'til it's over) . Cancer Prev Res (Phila) vol. 3 , ( 6 ) 689 - 691 .
Shan L, Ambroisine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S et al. ( 2010 ) . The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer . Prostate Cancer Prostatic Dis vol. 13 , ( 2 ) 117 - 125 .
Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, Wolmark N, Dowsett M et al. ( 2010 ) . Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach . JOURNAL OF CLINICAL ONCOLOGY . vol. 28 ,
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J et al. ( 2010 ) . Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial . Lancet vol. 375 , ( 9726 ) 1624 - 1633 .
Cuzick J ( 2010 ) . Long-term cervical cancer prevention strategies across the globe . Gynecol Oncol vol. 117 , ( 2 Suppl ) S11 - S14 .
Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, Ambroisine L, Fisher G et al. ( 2010 ) . PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention . Genes Cancer vol. 1 , ( 5 ) 444 - 464 .
Atkin WS, Cuzick J, Duffy SW, Edwards R, Hart A, Kralj-Hans I, Northover JM, Wardle J et al. ( 2010 ) . UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer Incidence and Mortality Rates at 11 Years After a Single Screening Examination . GASTROENTEROLOGY . vol. 138 , S53 - S53 .
Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G et al. ( 2010 ) . Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study . Br J Cancer vol. 102 , ( 9 ) 1405 - 1410 .
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A et al. ( 2010 ) . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol vol. 28 , ( 11 ) 1829 - 1834 .
Cuzick J, Castañón A, Sasieni P ( 2010 ) . Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK . Br J Cancer vol. 102 , ( 5 ) 933 - 939 .
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S et al. ( 2010 ) . Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial . Lancet Oncol vol. 11 , ( 3 ) 249 - 257 .
Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P et al. ( 2010 ) . Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer . Br J Cancer vol. 102 , ( 4 ) 678 - 684 .
Thomsen MK, Ambroisine L, Wynn S, Cheah KSE, Foster CS, Fisher G, Berney DM, Møller H et al. ( 2010 ) . SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation . Cancer Res vol. 70 , ( 3 ) 979 - 987 .
Stankiewicz E, Prowse DM, Cuzick J, Ambroisine L, Kudahetti S, Watkin N, Corbishley C, Berney DM ( 2010 ) . The RB/p16 Pathway but Not p53 Is Disrupted by High Risk HPV in Penile Squamous Cell Carcinoma . MODERN PATHOLOGY . vol. 23 , 221A - 221A .
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M et al. ( 2010 ) . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J Clin Oncol vol. 28 , ( 3 ) 509 - 518 .
Sasieni P, Castañón A, Cuzick J ( 2010 ) . ACOG guidelines on cervical screening: a step in the right direction . J Med Screen vol. 17 , ( 2 ) 55 - 56 .
Cuzick J ( 2010 ) . Controversies in design and interpretation of adjuvant clinical trials . Cancer Invest vol. 28 Suppl 1 , 28 - 34 .
Harvie M, Pegington M, Cuzick J, Frystyk J, Flyvbjerg A, Jebb S, Mattson M, Howell A ( 2010 ) . Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers . BREAST CANCER RESEARCH . vol. 12 , S9 - S10 .
Kudahetti SC, Fisher G, Ambroisine L, Prowse D, Kattan MW, Foster CS, Møller H, Oliver T et al. ( 2010 ) . Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer . Pathology vol. 42 , ( 6 ) 519 - 523 .
Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al. ( 2010 ) . Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast . Journal of the National Cancer Institute - Monographs vol. 41 , 162 - 177 .
Distler W, Canzler U, Duffy SR, Howell A, Cuzick J, Baum M ( 2010 ) . Undesirable Gynaecological and Operative Interventions during Treatment of Breast Cancer with Anastrozole and Tamoxifen . GEBURTSH FRAUENHEILK vol. 70 , ( 1 ) 57 - 61 .
Sasieni P, Castañon A, Cuzick J ( 2010 ) . What is the right age for cervical cancer screening? . Womens Health (Lond) vol. 6 , ( 1 ) 1 - 4 .
Cuzick J ( 2009 ) . Advances in Preventive Therapy . CANCER RESEARCH . vol. 69 , 482S - 482S .
Cuzick J, Sestak I, Pinder SE, Ellis IO, Hackshaw A, Bundred NJ, Forbes JF, Bishop H et al. ( 2009 ) . Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results front the UK/ANZ DCIS Trial in Women with Locally Excised DCIS . CANCER RESEARCH . vol. 69 , 493S - 493S .
Stone J, Warren RML, Pinney E, Warwick J, Cuzick J ( 2009 ) . Determinants of percentage and area measures of mammographic density . Am J Epidemiol vol. 170 , ( 12 ) 1571 - 1578 .
Sestak I, Distler W, Forbes JF, Howell A, Cuzick J ( 2009 ) . Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer - A Retrospective Exploratory Analysis from the ATAC Trial . CANCER RESEARCH . vol. 69 , 553S - 553S .
Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A et al. ( 2009 ) . Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score - Results from TransATAC . CANCER RESEARCH . vol. 69 , 503S - 503S .
Cuzick J ( 2009 ) . Use of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: An Overview of the Randomized Trials . CANCER RESEARCH . vol. 69 , 532S - 532S .
Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE ( 2009 ) . How to evaluate emerging technologies in cervical cancer screening? . Int J Cancer vol. 125 , ( 11 ) 2489 - 2496 .
Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM ( 2009 ) . EUROGIN 2008 roadmap on cervical cancer prevention . Int J Cancer vol. 125 , ( 10 ) 2246 - 2255 .
Sestak I, Sapunar F, Cuzick J ( 2009 ) . Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial . J Clin Oncol vol. 27 , ( 30 ) 4961 - 4965 .
Foster CS, Dodson AR, Ambroisine L, Fisher G, Møller H, Clark J, Attard G, De-Bono J et al. ( 2009 ) . Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement . Br J Cancer vol. 101 , ( 7 ) 1137 - 1144 .
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S et al. ( 2009 ) . Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) . Eur Urol vol. 56 , ( 4 ) 584 - 591 .
Sasieni P, Castle PE, Cuzick J ( 2009 ) . Further analysis of the ARTISTIC trial . Lancet Oncol vol. 10 , ( 9 ) 841 - 842 .
Elliott P, Cuzick J, English D, Stern R ( 2009 ) . Geographical and Environmental Epidemiology: Methods for Small Area Studies .
Stankiewicz E, Kudahetti SC, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Watkin N et al. ( 2009 ) . HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis . Mod Pathol vol. 22 , ( 9 ) 1160 - 1168 .
Elliott P, Cuzick J, English D, Stern R ( 2009 ) . Introductory remarks by the editors .
Alexander FE, Cuzick J ( 2009 ) . Methods for the assessment of disease clusters . Geographical and Environmental Epidemiology: Methods for Small Area Studies ,
Cuzick J, Elliott P ( 2009 ) . Small-area studies: Purpose and methods . Geographical and Environmental Epidemiology: Methods for Small Area Studies ,
Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R et al. ( 2009 ) . Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer . Breast vol. 18 Suppl 2 , S1 - 11 .
Sasieni P, Castanon A, Cuzick J ( 2009 ) . Screening and adenocarcinoma of the cervix . INT J CANCER vol. 125 , ( 3 ) 525 - 529 .
Sasieni P, Castanon A, Cuzick J ( 2009 ) . Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data . BMJ vol. 339 ,
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C et al. ( 2009 ) . American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction . Journal of Oncology Practice vol. 5 , ( 4 ) 196 - 199 .
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C et al. ( 2009 ) . American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction . J Clin Oncol vol. 27 , ( 19 ) 3235 - 3258 .
Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Møller H, Kattan MW et al. ( 2009 ) . p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer . BJU Int vol. 104 , ( 1 ) 20 - 24 .
Arbyn M, Cuzick J ( 2009 ) . International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention . Cancer Lett vol. 278 , ( 1 ) 1 - 2 .
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C et al. ( 2009 ) . Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement . Lancet Oncol vol. 10 , ( 5 ) 501 - 507 .
Kerkhot M, Roobol MJ, Steyerberg EW, Cuzick J, Schroder FH ( 2009 ) . SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION . JOURNAL OF UROLOGY . vol. 181 , 233 - 233 .
Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J et al. ( 2009 ) . Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study . Br J Cancer vol. 100 , ( 6 ) 888 - 893 .
Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J et al. ( 2009 ) . Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk . J Natl Cancer Inst vol. 101 , ( 6 ) 384 - 398 .
Howell A, ForbeS J, Cuzick J, ATAC Investigators ( 2009 ) . Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population . BREAST vol. 18 , S51 - S51 .
Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX et al. ( 2009 ) . Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older . Int J Cancer vol. 124 , ( 3 ) 516 - 520 .
Ingle JN, Dowsett M, Cuzick J, Davies C ( 2009 ) . Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies . CANCER RESEARCH . vol. 69 , 66S - 66S .
Cuzick J, Warwick J, Pinney L, Warren R, Cawthorn S, Howell A, Duffy S ( 2009 ) . Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1 . CANCER RESEARCH . vol. 69 , 77S - 78S .
Sestak I, Cuzick J ( 2009 ) . Characteristics of carpal-tunnel syndrome in the ATAC trial . CANCER RESEARCH . vol. 69 , 326S - 326S .
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R et al. ( 2009 ) . Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study . CANCER RESEARCH . vol. 69 , 75S - 76S .
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Jebb S, Mattson M, Howell A ( 2009 ) . The effect of intermittent versus continuous energy restriction on biomarkers of breast cancer . CANCER RESEARCH . vol. 69 , 95S - 96S .
Duffy SR, Distler W, Howell A, Cuzick J, Baum M ( 2009 ) . A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial . Am J Obstet Gynecol . vol. 200 , 80.e1 - 80.e7 .
Oliver T, Lorinez A, Cuzick J ( 2009 ) . Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies . Recent Results Cancer Res . vol. 181 , 195 - 205 .
Howell A, Cuzick J ( 2009 ) . Risk factors. Introduction to Session 1 . Breast Cancer Res vol. 11 Suppl 3 ,
Rajab R, Fisher G, Ambroisine L, Foster CS, Moller H, Kattan M, Reuter V, Scardino P et al. ( 2009 ) . The Predictive Power of Prostate Cancer Extent Measurements in a Large Watchful Waiting Cohort . LABORATORY INVESTIGATION . vol. 89 , 190A - 190A .
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group ( 2008 ) . Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial . Lancet Oncol vol. 9 , ( 12 ) 1143 - 1148 .
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, Cuzick J ( 2008 ) . Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer . BRIT J CANCER vol. 99 , ( 10 ) 1572 - 1578 .
Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R et al. ( 2008 ) . Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears . Cancer Epidemiol Biomarkers Prev vol. 17 , ( 11 ) 3033 - 3042 .
Clark J, Attard G, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S et al. ( 2008 ) . ETS GENE TRANSLOCATIONS AND PROSTATE CANCER PROGNOSIS . ANTICANCER RES vol. 28 , ( 6B ) 4155 - 4156 .
Cuzick J ( 2008 ) . Hormone replacement therapy and the risk of breast cancer . Eur J Cancer vol. 44 , ( 16 ) 2344 - 2349 .
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, De Sanjose S, Naucler P et al. ( 2008 ) . Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study . BMJ vol. 337 , ( 7676 ) 969 - 972 .
Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, Naucler P et al. ( 2008 ) . Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study . BMJ vol. 337 ,
Kudahetti S, Fisher G, Ambroidine I, Kattan M, Foster C, Oliver T, Moller H, Reuter V et al. ( 2008 ) . Cell-cycle proteins as biomarkers in clinically localised prostate cancer patients managed conservatively-results from the trans-atlantic prostate group . HISTOPATHOLOGY . vol. 53 , 279 - 280 .
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ ( 2008 ) . Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II) . Lancet Oncol vol. 9 , ( 10 ) 953 - 961 .
Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G et al. ( 2008 ) . Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial . Lancet Oncol vol. 9 , ( 10 ) 937 - 945 .
Oliver T, Lorincz A, Cuzick J ( 2008 ) . CHEMO-PREVENTION OF: PROSTATE CANCER: THE RATIONALE BEHIND DESIGN OF PILOT STUDIES . ANTICANCER RES vol. 28 , ( 5C ) 3428 - 3429 .
Cuzick JM ( 2008 ) . DETERMINING THE OPTIMAL TIMING AND DURATION OF THE USE OF AN AROMATASE INHIBITOR (AI) IN THE ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE (HR plus ) BREAST CANCER (BC) USING MODELLING ANALYSES . ANNALS OF ONCOLOGY . vol. 19 , 87 - 87 .
Cuzick J ( 2008 ) . IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole . Expert Rev Anticancer Ther vol. 8 , ( 9 ) 1377 - 1385 .
Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group ( 2008 ) . Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis . Lancet Oncol vol. 9 , ( 9 ) 866 - 872 .
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, Dillner J, Meijer CJLM ( 2008 ) . Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries . Vaccine vol. 26 Suppl 10 , K29 - K41 .
Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim Y-T, Konno R, Parkin DM, Qiao Y-L et al. ( 2008 ) . Recommendations for cervical cancer prevention in Asia Pacific . Vaccine vol. 26 Suppl 12 , M89 - M98 .
Cuzick J ( 2008 ) . Use of LHRH-agonists as adjuvant therapy for breast cancer . Expert Opin Ther Targets vol. 12 , ( 8 ) 1065 - 1071 .
Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S et al. ( 2008 ) . Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer . Br J Cancer vol. 99 , ( 2 ) 314 - 320 .
Cuzick J ( 2008 ) . Primary endpoints for randomised trials of cancer therapy . Lancet vol. 371 , ( 9631 ) 2156 - 2158 .
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp ( 2008 ) . ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion . BREAST CANCER RESEARCH AND TREATMENT . vol. 109 , 590 - 590 .
Buzdar AU, Cuzick J ( 2008 ) . Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up . JOURNAL OF CLINICAL ONCOLOGY . vol. 26 ,
Grimison PS, Coates AS, Forbes JF, Cuzick J, Furnival C, Craft PS, Snyder RD, Thornton RM et al. ( 2008 ) . Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1) . JOURNAL OF CLINICAL ONCOLOGY . vol. 26 ,
Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G et al. ( 2008 ) . Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study . Int J Cancer vol. 122 , ( 10 ) 2294 - 2300 .
Cuzick J ( 2008 ) . Review of Swedish cervical cancer screening program demonstrates effectiveness and room for improvement . J NATL CANCER I vol. 100 , ( 9 ) 602 - 602 .
Cuzick J ( 2008 ) . Routine audit of large-scale cervical cancer screening programs . J Natl Cancer Inst vol. 100 , ( 9 ) 605 - 606 .
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D et al. ( 2008 ) . Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test . J Natl Cancer Inst vol. 100 , ( 7 ) 492 - 501 .
Cuzick J ( 2008 ) . Aromatase inhibitors in early breast-cancer treatment: The story so far . Breast vol. 17 Suppl 3 , S2 - S8 .
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walkers M, Cuzick J ( 2008 ) . Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis . EJC SUPPLEMENTS . vol. 6 , 216 - 216 .
Cuzick J ( 2008 ) . Optimal timing and duration of the use of an aromatase inhibitor (AI) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC) . EJC SUPPLEMENTS . vol. 6 , 121 - 121 .
Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J ( 2008 ) . Timing and severity of prominent side effects of anastrozole and tamoxifen . EJC SUPPLEMENTS . vol. 6 , 71 - 71 .
Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P et al. ( 2008 ) . Complex patterns of ETS gene alteration arise during cancer development in the human prostate . Oncogene vol. 27 , ( 14 ) 1993 - 2003 .
Franco EL, Cuzick J ( 2008 ) . Cervical cancer screening following prophylactic human papillomavirus vaccination . Vaccine vol. 26 Suppl 1 , A16 - A23 .
Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW et al. ( 2008 ) . Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 . J Clin Oncol . vol. 26 , 1051 - 1057 .
Oliver RTD, Lorincz A, Cuzick J ( 2008 ) . Prostate cancer prevention by short-term antiandrogens: A novel strategy . EJC SUPPLEMENTS . vol. 6 , 32 - 32 .
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J et al. ( 2008 ) . Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial . J Clin Oncol vol. 26 , ( 7 ) 1059 - 1065 .
Cuzick J ( 2008 ) . Use of aromatase inhibitors in breast cancer prevention . EJC SUPPLEMENTS . vol. 6 , 21 - 21 .
Eastham JA, Kattan MW, Fearn P, Fisher G, Berney DM, Oliver T, Foster CS, Moller H et al. ( 2008 ) . Local progression among men with conservatively treated localized prostate cancer: Results from the transatlantic prostate group . EUR UROL vol. 53 , ( 2 ) 347 - 354 .
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS et al. ( 2008 ) . Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer . Oncogene vol. 27 , ( 3 ) 253 - 263 .
Cuzick J ( 2008 ) . Assessing risk for breast cancer . Breast Cancer Res vol. 10 Suppl 4 ,
Cuzick J ( 2008 ) . Chemoprevention of breast cancer . Breast Cancer vol. 15 , ( 1 ) 10 - 16 .
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M ( 2008 ) . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial . Lancet Oncol vol. 9 , ( 1 ) 45 - 53 .
Singh S, Cuzick J, Ferguson S, Blake G, Truscott J, Coleman R, Eastel R, Howell A ( 2008 ) . Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) . CANCER TREATMENT REVIEWS . vol. 34 , S53 - S54 .
Eastell R, Adams JE, Clack G, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann M et al. ( 2008 ) . Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial . CALCIFIED TISSUE INT vol. 82 , S84 - S84 .
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C et al. ( 2008 ) . KI-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer . LABORATORY INVESTIGATION . vol. 88 , 148A - 148A .
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C et al. ( 2008 ) . Ki-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer . MODERN PATHOLOGY . vol. 21 , 148A - 148A .
Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V et al. ( 2008 ) . Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent . CANCER vol. 112 , ( 1 ) 69 - 74 .
Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R ( 2008 ) . Response and resistance to the endocrine prevention of breast cancer . Adv Exp Med Biol . vol. 617 , 201 - 211 .
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A ( 2008 ) . The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial . BREAST CANCER RESEARCH . vol. 10 , S27 - S28 .
Duffy SW, Nagtegaal ID, Astley SM, Gillan MGC, McGee MA, Boggis CRM, Wilson M, Beetles UM et al. ( 2008 ) . Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view . Breast Cancer Res vol. 10 , ( 4 )
Giorgi-Rossi P, Segnan N, Zappa M, Naldoni C, Zorzi M, Confortini M, Merito M, Cuzick J et al. ( 2007 ) . The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective . Int J Cancer vol. 121 , ( 12 ) 2729 - 2734 .
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp ( 2007 ) . ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion . BREAST CANCER RESEARCH AND TREATMENT . vol. 106 , S12 - S13 .
Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R, Howell A ( 2007 ) . Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) . BREAST CANCER RESEARCH AND TREATMENT . vol. 106 , S9 - S9 .
Cuzick J ( 2007 ) . Hormone replacement therapy and breast cancer - a summary of results from other studies . BREAST CANCER RESEARCH AND TREATMENT . vol. 106 , S3 - S3 .
Cuzick J ( 2007 ) . Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial . BREAST CANCER RESEARCH AND TREATMENT . vol. 106 , S108 - S108 .
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P et al. ( 2007 ) . Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading . BJU Int vol. 100 , ( 6 ) 1240 - 1244 .
Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J, ATAC Trialists Grp ( 2007 ) . The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial . BREAST CANCER RESEARCH AND TREATMENT . vol. 106 , S109 - S109 .
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P et al. ( 2007 ) . Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome . Histopathology vol. 51 , ( 4 ) 452 - 457 .
Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, Naldoni C, Segnan N et al. ( 2007 ) . The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment . Gynecol Oncol vol. 107 , ( 1 Suppl 1 ) S230 - S232 .
Cuzick J ( 2007 ) . Adjusting for non-compliance and contamination in randomised clinical trials (vol 16, pg 1017, 1997) . STAT MED vol. 26 , ( 20 ) 3821 - 3821 .
Sestak I, Edwards R, Howell A, Cuzick J ( 2007 ) . Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer . EJC SUPPLEMENTS . vol. 5 , 31 - 31 .
Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P ( 2007 ) . Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru . Int J Cancer vol. 121 , ( 4 ) 796 - 802 .
Cuzick J ( 2007 ) . The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer . Expert Rev Anticancer Ther vol. 7 , ( 8 ) 1089 - 1094 .
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P et al. ( 2007 ) . Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial . BMJ vol. 335 , ( 7609 )
Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schröder FH ( 2007 ) . Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial . Prostate vol. 67 , ( 10 ) 1053 - 1060 .
Cuzick J, Sasieni P, Howell A ( 2007 ) . Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen? . JOURNAL OF CLINICAL ONCOLOGY . vol. 25 ,
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF et al. ( 2007 ) . Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model . Endocr Relat Cancer vol. 14 , ( 2 ) 169 - 187 .
LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R ( 2007 ) . Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials . Lancet vol. 369 , ( 9574 ) 1711 - 1723 .
Cuzick J ( 2007 ) . Mammographic breast density . N Engl J Med vol. 356 , ( 18 ) 1885 - 1887 .
Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T ( 2007 ) . International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients . BJU Int vol. 99 , ( 5 ) 1056 - 1065 .
Donovan MJ, Hamann S, Clayton M, Teverovskiy M, Vengrenyuk Y, Khan F, Eggener SE, Reuter VE et al. ( 2007 ) . Predicting disease specific survival at the time of diagnosis utilizing clinical variables integrated with quantitative immunofluorescence . JOURNAL OF UROLOGY . vol. 177 , 590 - 590 .
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators ( 2007 ) . Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial . J Natl Cancer Inst vol. 99 , ( 4 ) 272 - 282 .
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A et al. ( 2007 ) . HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology . Eur J Cancer vol. 43 , ( 3 ) 476 - 480 .
Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H ( 2007 ) . Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study . BMC Cancer vol. 7 ,
Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J ( 2007 ) . The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions . Br J Cancer vol. 96 , ( 1 ) 110 - 117 .
Cuzick J ( 2007 ) . Aromatase inhibitors in the treatment of breast cancer: Results of the ATAC trial . Nature Clinical Practice Oncology vol. 4 , ( SUPPL. 1 )
Cuzick J ( 2007 ) . Comparison between initial therapy with an aromatase inhibitor and sequential treatment after tamoxifen . Nature Clinical Practice Oncology vol. 4 , ( SUPPL. 1 )
Sestk I, Edwards R, Howell A, Cuzick J ( 2007 ) . Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial . BREAST CANCER RESEARCH . vol. 9 ,
Cuzick J, Sasieni P, Myles J, Tyrer J ( 2007 ) . Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination . J ROY STAT SOC B vol. 69 , 565 - 588 .
Howell A, Clarke RB, Evans G, Bundred N, Cuzick J, Santen R, Allred C ( 2007 ) . Estrogen deprivation for breast cancer prevention . Recent Results Cancer Res vol. 174 , 151 - 167 .
Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, Wardle J, Altman DG et al. ( 2007 ) . Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting . J Med Screen vol. 14 , ( 1 ) 34 - 42 .
Cuzick J, Cafferty FH, Edwards R, Møller H, Duffy SW ( 2007 ) . Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial . J Med Screen vol. 14 , ( 4 ) 178 - 185 .
Chapman M, Howelli A, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Harvie M ( 2007 ) . The effect of intermittent v. chronic energy restriction on weight loss in premenopausal women: preliminary results from a randomised pilot trial to reduce breast cancer risk . P NUTR SOC vol. 66 , 99A - 99A .
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebbs S, Parfitt G, Howell A ( 2007 ) . The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomized pilot trial . JOURNAL OF NUTRITION . vol. 137 , 283S - 283S .
Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialistsa9 Group ( 2006 ) . Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer . Breast Cancer Res Treat vol. 100 , ( 3 ) 273 - 284 .
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V et al. ( 2006 ) . Long-term outcome among men with conservatively treated localised prostate cancer . Br J Cancer vol. 95 , ( 9 ) 1186 - 1194 .
Cuzick J ( 2006 ) . Chemoprevention of breast cancer . Womens Health (Lond) vol. 2 , ( 6 ) 853 - 861 .
Cox T, Cuzick J ( 2006 ) . HPV DNA testing in cervical cancer screening: from evidence to policies . Gynecol Oncol . vol. 103 , 8 - 11 .
Rajkumar T, Cuzick J, Appleby P, Barnabas R, Beral V, Berrington De González A, Bull D, Canfell K et al. ( 2006 ) . Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies . International Journal of Cancer vol. 119 , ( 5 ) 1108 - 1124 .
Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P et al. ( 2006 ) . Overview of the European and North American studies on HPV testing in primary cervical cancer screening . INT J CANCER vol. 119 , ( 5 ) 1095 - 1101 .
Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J ( 2006 ) . Chapter 10: New dimensions in cervical cancer screening . Vaccine vol. 24 Suppl 3 , S3/90 - S3/97 .
Franco EL, Cuzick J, Hildesheim A, de Sanjosé S ( 2006 ) . Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination . Vaccine vol. 24 Suppl 3 , S3/171 - S3/177 .
Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC ( 2006 ) . Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer . Vaccine vol. 24 Suppl 3 , S3/242 - S3/249 .
Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A ( 2006 ) . Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts . Vaccine vol. 24 Suppl 3 , S3/251 - S3/261 .
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J ( 2006 ) . Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms . J Clin Oncol . vol. 24 , 3991 - 3996 .
Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J et al. ( 2006 ) . Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial . Lancet Oncol vol. 7 , ( 8 ) 633 - 643 .
Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P ( 2006 ) . Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer . Curr Med Res Opin vol. 22 , ( 8 ) 1575 - 1585 .
Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group ( 2006 ) . Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) . J Bone Miner Res vol. 21 , ( 8 ) 1215 - 1223 .
Buzdar AU, Guastalla J-P, Nabholtz J-M, Cuzick J, ATAC Trialists' Group ( 2006 ) . Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial . Cancer vol. 107 , ( 3 ) 472 - 480 .
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C et al. ( 2006 ) . Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial . Lancet Oncol vol. 7 , ( 7 ) 547 - 555 .
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A et al. ( 2006 ) . Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial . J Natl Cancer Inst vol. 98 , ( 11 ) 765 - 774 .
Cuzick J, Forbes JF, Howell A ( 2006 ) . Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study . J Natl Cancer Inst vol. 98 , ( 9 )
Buzdar AU, Baum M, Cuzick J ( 2006 ) . Letrozole or tamoxifen in early breast cancer . N Engl J Med vol. 354 , ( 14 ) 1528 - 1530 .
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M, Buzdar A ( 2006 ) . Progesterone receptor and human epidermal growth factor receptor 2 status: An independent influence on the efficacy of endocrine therapy in breast cancer? Reply . J CLIN ONCOL vol. 24 , ( 9 ) 1482 - 1482 .
Houssami N, Cuzick J, Dixon JM ( 2006 ) . The prevention, detection, and management of breast cancer . Med J Aust vol. 184 , ( 5 ) 230 - 234 .
Cuzick J, Sasieni P, Howell A ( 2006 ) . Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? . Br J Cancer vol. 94 , ( 4 ) 460 - 464 .
Buzdar AU, Cuzick J ( 2006 ) . Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data . Clin Cancer Res . vol. 12 , 1037s - 1048s .
Cuzick J ( 2006 ) . Keynote comment: Chemoprevention of cancer--time to catch up with the cardiologists . Lancet Oncol vol. 7 , ( 2 ) 98 - 99 .
Howell A, Cuzick J ( 2006 ) . Vascular effects of aromatase inhibitors: Data from clinical trials (vol 95, pg 143, 2005) . J STEROID BIOCHEM vol. 98 , ( 2-3 ) 180 - 180 .
Cuzick J, Wale C, ATAC Trialists' Group ( 2006 ) . A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S24 - S24 .
Ronco G, Segnan N, Confortini M, Giorgi-Rossi P, Vettorazzi M, Naldoni C, Palma PD, Cuzick J ( 2006 ) . A randomises trial on HPV testing for primary cervical screening: Data at recruitment . EUR J EPIDEMIOL vol. 21 , 53 - 53 .
Cuzick J ( 2006 ) . Bone versus breast density . Breast Cancer Res vol. 8 , ( 3 )
Gao JN, Forbes JF, Warren RML, Cuzick J, Howell A, D'Este C, Warren-Forward H ( 2006 ) . Change in marnmographic density after cessation of tamoxifen: results from international breast cancer intervention study I (IBIS I) . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S56 - S56 .
Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J ( 2006 ) . Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S55 - S55 .
Singh S, Richmond B, Howell A, Cuzick J ( 2006 ) . Effect of anastrozole on cholesterol fractions in postmenopausal women with high risk of breast cancer: results from IBIS-II breast cancer prevention study . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S57 - S57 .
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A ( 2006 ) . Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomised pilot trial . BREAST CANCER RESEARCH . vol. 8 , S14 - S14 .
Berney DM, Fisher G, Cuzick J, Scardino P, Kattan M, Reuter V, Foster CS ( 2006 ) . Gleason score and survival in conservatively treated localised prostate cancer . MODERN PATHOLOGY . vol. 19 , 130A - 130A .
Cuzick J, IBIS Investigators ( 2006 ) . Long term efficacy of tamoxifen for chemoprevention - results of the IBIS-I study . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S16 - S17 .
Berney DM, Cuzick J, Scardino P, Fisher G, Kattan M, Foster CS, Reuter V ( 2006 ) . Pitfalls in the diagnosis of prostate cancer. A review of 1861 cases . LABORATORY INVESTIGATION . vol. 86 , 130A - 130A .
Cuzick J, Warren R, Pinney L, Warwick J, Howell A ( 2006 ) . The effect of anastrozole, tamoxifen or a combination of both drugs on mammographic breast density in post menopausal women with breast cancer . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S224 - S224 .
Cuzick J, LHRH-Agonist Overview Group ( 2006 ) . The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomized trials . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S10 - S10 .
Singh S, Howell A, Cuzick J ( 2006 ) . Vit D levels among patients with Arthralgia: results from IBIS-II breast cancer prevention study . BREAST CANCER RESEARCH AND TREATMENT . vol. 100 , S61 - S61 .
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K et al. ( 2005 ) . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials . LANCET vol. 366 , ( 9503 ) 2087 - 2106 .
Buzdar AU, Cuzick J ( 2005 ) . Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer . J Clin Oncol vol. 23 , ( 33 ) 8544 - 8546 .
Forbes JF, Cuzick J ( 2005 ) . Systemic adjuvant therapies for early breast cancer: 15-year results for recurrence and survival . Med J Aust vol. 183 , ( 9 ) 447 - 448 .
Cuzick J ( 2005 ) . Breast cancer prevention - Beyond tamoxifen . CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION . vol. 14 , 2804S - 2804S .
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M ( 2005 ) . Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study . J Clin Oncol vol. 23 , ( 30 ) 7512 - 7517 .
Cuzick J ( 2005 ) . Can HPV testing challenge the PAP smear? . EJC SUPPL vol. 3 , ( 2 ) 9 - 9 .
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn H, Albain KS, Bergh J et al. ( 2005 ) . Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 . ANN ONCOL vol. 16 , ( 10 ) 1569 - 1583 .
Cuzick J ( 2005 ) . The implications of delaying the start of aromatase inhibitor (AI) therapy . EJC SUPPL vol. 3 , ( 2 ) 109 - 110 .
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A et al. ( 2005 ) . A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe . Eur J Cancer vol. 41 , ( 14 ) 2141 - 2149 .
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A et al. ( 2005 ) . Sunbed use and melanoma: a multi-centre case-control study of melanoma in Europe . BRITISH JOURNAL OF DERMATOLOGY . vol. 153 , 2 - 2 .
Baum M, Cuzick J, Howell A, Buzdar A, Demicheli R, Greco M, Retsky M, Hrushesky B et al. ( 2005 ) . An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 31S - 31S .
Kattan MW, Cuzick J, Scardino PT, Transatlantic Prostate Grp ( 2005 ) . Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 381S - 381S .
Cuzick J, Howell A ( 2005 ) . Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 43S - 43S .
Cuzick J, Duffy S, Tyrer J ( 2005 ) . A breast cancer prediction model - Authors' reply . STAT MED vol. 24 , ( 10 ) 1612 - 1612 .
Cuzick J ( 2005 ) . Interaction of statisticians with DMCs . Stat Med vol. 24 , ( 10 )
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K et al. ( 2005 ) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . LANCET vol. 365 , ( 9472 ) 1687 - 1717 .
Howell A, Cuzick J ( 2005 ) . Vascular effects of aromatase inhibitors: Data from clinical trials . JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY vol. 95 , ( 1-5 ) 143 - 149 .
Cuzick J ( 2005 ) . Forest plots and the interpretation of subgroups . Lancet vol. 365 , ( 9467 )
Cuzick J ( 2005 ) . Anastrozole . DRUG TODAY vol. 41 , ( 4 ) 227 - 239 .
Cuzick J ( 2005 ) . Radiotherapy for breast cancer . J NATL CANCER I vol. 97 , ( 6 ) 406 - 407 .
Cuzick J ( 2005 ) . Aromatase inhibitors for breast cancer prevention . J CLIN ONCOL vol. 23 , ( 8 ) 1636 - 1643 .
Tyrer J, Duffy SW, Cuzick J ( 2005 ) . A breast cancer prediction model incorporating familial and personal risk factors (vol 23, pg 1111, 2004) . STAT MED vol. 24 , ( 1 ) 156 - 156 .
Cuzick J ( 2005 ) . Chemoprevention: beyond tamoxifen . BREAST CANCER RESEARCH . vol. 7 , S9 - S9 .
Cuzick J, Howell A, Forbes J ( 2005 ) . Early stopping of clinical trials . BREAST CANCER RES vol. 7 , ( 5 ) 181 - 183 .
Shaw GL, Cuzick J, Prapotnich D, Spry N, Tucker S, Zerbib M, Goldenberg SL, Malone S et al. ( 2005 ) . International study of the use of intermittent hormone therapy for cancer of the prostate (ISICAP) . ANNALS OF ONCOLOGY . vol. 16 , 294 - 294 .
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I et al. ( 2005 ) . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer . LANCET vol. 365 , ( 9453 ) 60 - 62 .
SASIENI P, Cuzick J ( 2005 ) . Screening . Introduction to the cellular and molecular biology of cancer. , Editors: Knowles, M, Selby, P , Edition. 4th , Oxford University Press ( Oxford ),
CUZICK JM ( 2005 ) . Testing Times (Book reviews on 'Should I be tested for Cancer?' by H Gilbert Welch) . Lancet Oncology vol. 6 , 12 - 13 .
Sestak I, Kealy R, Edwards R, Cuzick J ( 2005 ) . The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms . BREAST CANCER RESEARCH AND TREATMENT . vol. 94 , S11 - S12 .
Terry G, Ho L, Londesborough P, Cross P, Lopes A, Monaghan J, Cuzick J ( 2004 ) . The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions . Br J Cancer vol. 91 , ( 12 ) 2056 - 2062 .
Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A ( 2004 ) . Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial . J Clin Oncol vol. 22 , ( 21 ) 4261 - 4271 .
Locker GY, Sainsbury JR, Cuzick J, ATAC Trialists' Group ( 2004 ) . Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy . Cancer vol. 101 , ( 4 ) 735 - 740 .
Sainsbury R, Locker G, Cuzick J, ATAC Trialists Grp ( 2004 ) . The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 26S - 26S .
Atkin W, Rogers P, Cardwell C, Cook C, Cuzick J, Wardle J, Edwards R ( 2004 ) . Wide variation in adenoma detection rates at screening flexible sigmoidoscopy . Gastroenterology vol. 126 , ( 5 ) 1247 - 1256 .
Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW ( 2004 ) . Tamoxifen and breast density in women at increased risk of breast cancer . J NATL CANCER I vol. 96 , ( 8 ) 621 - 628 .
Tyrer J, Duffy SW, Cuzick J ( 2004 ) . A breast cancer prediction model incorporating familial and personal risk factors . Stat Med vol. 23 , ( 7 ) 1111 - 1130 .
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M et al. ( 2004 ) . Adjuvant use of anastrozole in breast cancer . J Clin Oncol vol. 22 , ( 8 ) 1524 - 1526 .
Sasieni P, Adams J, Cuzick J ( 2004 ) . Reply: The value of case-control audits of screening . BRIT J CANCER vol. 90 , ( 5 ) 1109 - 1110 .
Bataille V, Winnett A, Sasieni P, Bishop JAN, Cuzick J ( 2004 ) . Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study . EUR J CANCER vol. 40 , ( 3 ) 429 - 435 .
Fielder HM, Warwick J, Brook D, Gower-Thomas K, Cuzick J, Monypenny I, Duffy SW ( 2004 ) . A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales . J Med Screen vol. 11 , ( 4 ) 194 - 198 .
Cuzick J ( 2004 ) . Chemoprevention of breast cancer . BIOMED PHARMACOTHER vol. 58 , ( 1 ) 71 - 71 .
Cuzick J, DUFFY SW, Warren RML, Pinney E, Warwick J ( 2004 ) . Effect of tamoxifen on women at increased risk of breast cancer . J Natl. Cancer Institute. vol. 96 , 621 - 628 .
CUZICK JM, Hamed H, O'neill C ( 2004 ) . Genetic and other factors related to tamoxifen-associated venous thromboembolic . The American Journal of Oncology Review. vol. 3 , 405 - 406 .
CUZICK JM ( 2004 ) . Screening for cervical cancer . Cervical Cancer: From Etiology to Prevention. T. E. Rohan & K. V. Shah (eds). , Kluwer Academic Publishers.
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U et al. ( 2003 ) . Management of women who test positive for high-risk types of human papillomavirus: the HART study . LANCET vol. 362 , ( 9399 ) 1871 - 1876 .
Cuzick J ( 2003 ) . Epidemiology of breast cancer - selected highlights . BREAST vol. 12 , ( 6 ) 405 - 411 .
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J et al. ( 2003 ) . The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data . BJOG vol. 110 , ( 12 ) 1099 - 1106 .
Cuzick J ( 2003 ) . Treatment of DCIS--results from clinical trials . Surg Oncol vol. 12 , ( 4 ) 213 - 219 .
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group ( 2003 ) . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses . Cancer vol. 98 , ( 9 ) 1802 - 1810 .
Duggan C, Marriott K, Edwards R, Cuzick J ( 2003 ) . Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer . J CLIN ONCOL vol. 21 , ( 19 ) 3588 - 3593 .
Cuzick J, O'Neill C, Howell T, Forbes J ( 2003 ) . Anastrozole for ductal carcinoma in situ . LANCET vol. 362 , ( 9386 ) 832 - 833 .
Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M et al. ( 2003 ) . Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer . Eur J Cancer vol. 39 , ( 12 ) 1711 - 1717 .
Sasieni P, Cuzick J ( 2003 ) . The UK breast-screening programme should start at age 47 years . LANCET vol. 362 , ( 9379 ) 246 - 247 .
Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party et al. ( 2003 ) . Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial . Lancet vol. 362 , ( 9378 ) 95 - 102 .
Sasieni P, Adams J, Cuzick J ( 2003 ) . Benefit of cervical screening at different ages: evidence from the UK audit of screening histories . BRIT J CANCER vol. 89 , ( 1 ) 88 - 93 .
De Vries E, Boniol M, Severi G, Brandberg Y, Eggermont A, Ringborg U, Grivegnee A, Coebergh JW et al. ( 2003 ) . Sunbed use in melanoma cases and controls in Europe: a European Union multicentre case-control study . BRITISH JOURNAL OF DERMATOLOGY . vol. 149 , 87 - 88 .
Warwick J, Pinney E, Warren RML, Duffy SW, Howell A, Wilson M, Cuzick J ( 2003 ) . Breast density and breast cancer risk factors in a high-risk population . BREAST vol. 12 , ( 1 ) 10 - 16 .
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P ( 2003 ) . Overview of the main outcomes in breast-cancer prevention trials . LANCET vol. 361 , ( 9354 ) 296 - 300 .
Cuzick J, Forbes J, Howell A, IBIS Investigators ( 2003 ) . Tamoxifen for breast-cancer prevention - Reply . LANCET vol. 361 , ( 9352 ) 178 - 178 .
Cuzick J ( 2003 ) . Aromatase inhibitors in prevention - Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second international breast cancer intervention study) . TUMOR PREVENTION AND GENETICS . Editors: Senn, HJ, Morant, R , vol. 163 , 96 - 103 .
CUZICK JM ( 2003 ) . Breast Cancer Prevention Trials . Evidence-Based Oncology. Williams C (Eds). , BMJ Publishing Group
CUZICK JM, Baum M, Houghton J ( 2003 ) . Chapter 6. Design and statistical considerations . History and Advancement of Anastrozole in the treatment of Breast Cancer. Buzlar A and Baum M. (Eds). , Royal Society of Medicine Press Ltd ( London ),
CUZICK JM ( 2003 ) . Chemoprevention of Breast Cancer . The American Journal of Oncology Review vol. 2 , 319 - 321 .
Sasieni P, CUZICK JM ( 2003 ) . Epidemiology of gynaecological cancer . Gynaecology (3rd ed) Shaw RW, Soutter WP, Stanton SL (Eds). , Churchill Livingstone ( London ),
CUZICK JM ( 2003 ) . Human Papilloma Screening for lower genital tract neoplasia . Lower Genital Tract Neoplasia. Maclean A, Singer A and Critchley H (Eds). , Royal College of Obstetricians and Gynaecology Press
Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A ( 2003 ) . Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears . J MED VIROL vol. 69 , ( 1 ) 118 - 121 .
CUZICK JM, Veronesi U, Boyle P, Ashley S, Powles T, Forbes J, Edwards R ( 2003 ) . Overview of the main outcomes in breast cancer prevention trials . Obstet Gynae Survey vol. 58 , ( 7 ) 463 - 465 .
Sauerbrei W, Schumacher M, Cuzick J, Jonat W, Kaufmann M ( 2003 ) . Prognostic factors determine groups with different prognoses in pre- and perimenopausal women with estrogen receptor-positive, node-positive breast cancer treated with goserelin (Zoladex (R)) or CMF - results from the ZEBRA study . BREAST CANCER RESEARCH AND TREATMENT . vol. 82 , S121 - S121 .
Wardle J, Williamson S, Sutton S, Biran A, McCaffery K, Cuzick J, Atkin W ( 2003 ) . Psychological impact of colorectal cancer screening . HEALTH PSYCHOL vol. 22 , ( 1 ) 54 - 59 .
CUZICK JM ( 2003 ) . Vaccination against cervical cancer - trial boost hopes [Editorial] . Trends in Urology Gynaecology and Sexual Health vol. 8 , 5 - 6 .
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC et al. ( 2002 ) . Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study . J Clin Oncol vol. 20 , ( 24 ) 4628 - 4635 .
Locker G, Sainsbury R, Cuzick J, ATAC Trialists' Grp ( 2002 ) . Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy . BREAST CANCER RESEARCH AND TREATMENT . vol. 76 , S35 - S35 .
Kaufmann M, Jonat W, Blarney R, Cuzick J, Fogelman I, De Haes J, Namer M, Sauerbrei W et al. ( 2002 ) . Updated survival results from the Zebra trial . BREAST CANCER RESEARCH AND TREATMENT . vol. 76 , S73 - S73 .
Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM et al. ( 2002 ) . Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease . Br J Cancer vol. 87 , ( 11 ) 1234 - 1245 .
Ashton HA, Buxton MJ, Campbell HE, Day NE, Kim LG, Marteau TM, Scott RAP, Thompson SG et al. ( 2002 ) . Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial . BRIT MED J vol. 325 , ( 7373 ) 1135 - 1138B .
Cuzick J ( 2002 ) . Prevention of breast cancer . EUROPEAN JOURNAL OF CANCER . vol. 38 , S85 - S86 .
Cuzick J ( 2002 ) . Rationale for a study testing aromatase inhibitors in prevention and DCIS . EUROPEAN JOURNAL OF CANCER . vol. 38 , S81 - S81 .
Cuzick J ( 2002 ) . Role of HPV testing in clinical practice . Virus Res . vol. 89 , 263 - 269 .
Eccles DM, Dowsett M, Howell A, Evans G, Chapman K, Eeles R, Mackay J, Fallowfield L et al. ( 2002 ) . The raloxifene plus zoladex (RAZOR) trial for breast cancer risk reduction . CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION . vol. 11 , 1194S - 1194S .
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A et al. ( 2002 ) . First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial . Lancet vol. 360 , ( 9336 ) 817 - 824 .
Eastell R, Hannon RA, Cuzick J, Clack G, Adams JE ( 2002 ) . Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) study . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 17 , S165 - S165 .
Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP ( 2002 ) . The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases . Histopathology vol. 41 , ( 3A ) 59 - 81 .
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM, Sahmoud T, ATAC Trialists' Group ( 2002 ) . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial . Lancet vol. 359 , ( 9324 ) 2131 - 2139 .
Cuzick J ( 2002 ) . Breast cancer screening--time to move forward . Breast vol. 11 , ( 3 ) 209 - 210 .
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin ( 2002 ) . Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial . LANCET vol. 359 , ( 9314 ) 1291 - 1300 .
Cuzick J ( 2002 ) . Update on new studies in Europe . EUR J CANCER vol. 38 , S44 - S44 .
Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, Sherman ME, Stoler MH et al. ( 2002 ) . Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom . Cancer . vol. 96 , 14 - 20 .
Terry G, Ho L, Londesborough P, Cuzick J ( 2002 ) . Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions . Br J Cancer vol. 86 , ( 3 ) 376 - 381 .
Sasieni PD, Adams J, Cuzick J ( 2002 ) . Avoidance of premature death: a new definition for the proportion cured . J Cancer Epidemiol Prev vol. 7 , ( 4 ) 165 - 171 .
Sasieni P, Cuzick J ( 2002 ) . Cervical cancer - Could HPV testing become the sole primary cervical screening test? . J MED SCREEN vol. 9 , ( 2 ) 49 - 51 .
Duffy SW, Cuzick J, Tabar L, Vitak B, Chen THH, Yen MF, Smith RA ( 2002 ) . Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes . J ROY STAT SOC C-APP vol. 51 , 235 - 243 .
Sasieni P, Cuzick J ( 2002 ) . Could HPV testing become the sole primary cervical screening test? . J Med Screen vol. 9 , ( 2 ) 49 - 51 .
Cuzick J, International Breast Cancer Intervention Study ( 2001 ) . A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials . Ann N Y Acad Sci . vol. 949 , 123 - 133 .
Cuzick J, Sasieni P ( 2001 ) . Natural history of cervical human papillomavirus . Lancet vol. 358 , ( 9292 ) 1550 - 1551 .
Cuzick J ( 2001 ) . Time to consider HPV testing in cervical screening . Ann Oncol vol. 12 , ( 11 ) 1511 - 1514 .
Duffy SW, Cuzick J ( 2001 ) . Let's talk about mammographic screening over again - response . BREAST vol. 10 , ( 5 ) 450 - 451 .
Bosch FX, Muñoz N, de Sanjosé S, Franco EL, Lowy DR, Schiffman M, Franceschi S, Kjaer SK et al. ( 2001 ) . Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer . J Natl Cancer Inst vol. 93 , ( 17 ) 1349 - 1350 .
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A ( 2001 ) . Detection of high-risk HPV types by the hybrid capture 2 test . J Med Virol vol. 65 , ( 1 ) 155 - 162 .
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A ( 2001 ) . Fatal adenovirus type 7b infection in a child with Smith-Lemli-Opitz syndrome . Journal of Medical Virology vol. 65 , ( 1 ) 66 - 69 .
Dowsett M, Cuzick J, Howell A, Jackson I, ATAC Trialists' Group ( 2001 ) . Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial . Br J Cancer vol. 85 , ( 3 ) 317 - 324 .
Cuzick J, George WD, Houghton J, DCIS Working Party ( 2001 ) . UKCCCR trial of tamoxifen and/or radiotherapy for DCIS . BRIT J CANCER vol. 85 , 2 - 2 .
Cuzick J ( 2001 ) . Is hormone replacement therapy safe for breast cancer patients? . J Natl Cancer Inst vol. 93 , ( 10 ) 733 - 734 .
Sasieni P, Cuzick J ( 2001 ) . Routine audit is an ethical requirement of screening . BMJ vol. 322 , ( 7295 )
Cuzick J ( 2001 ) . A strong law for weighted sums of I.I.D. random variables (vol 8, pg 625, 1995) . J THEOR PROBAB vol. 14 , ( 2 ) 605 - 605 .
Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J ( 2001 ) . Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials . J Clin Oncol vol. 19 , ( 7 ) 1885 - 1892 .
Cuzick J ( 2001 ) . Event-based analysis times for randomised clinical trials . BIOMETRIKA vol. 88 , ( 1 ) 245 - 253 .
Szarewski A, Maddox P, Royston P, Jarvis M, Anderson M, Guillebaud J, Cuzick J ( 2001 ) . The effect of stopping smoking on cervical Langerhans' cells and lymphocytes . BJOG vol. 108 , ( 3 ) 295 - 303 .
Atkin WS, Edwards R, Wardle J, Northover JM, Sutton S, Hart AR, Williams CB, Cuzick J ( 2001 ) . Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening . J Med Screen vol. 8 , ( 3 ) 137 - 144 .
Mackay J, Rogers C, Fielder H, Blamey R, Macmillan D, Boggis C, Brown J, Pharoah PD et al. ( 2001 ) . Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer . J Epidemiol Biostat vol. 6 , ( 5 ) 365 - 369 .
Cuzick J ( 2001 ) . HPV testing in cervical screening . Pharmacoepidemiol Drug Saf vol. 10 , ( 1 ) 33 - 36 .
De Nigris A, Paladini G, Duffy SW, Cuzick J ( 2001 ) . Letter to the editor (multiple lettes) [1] . Breast vol. 10 , ( 5 ) 450 - 451 .
Cuzick J ( 2000 ) . The classic approach . Cancer vol. 89 , ( 11 SUPPL. ) 2397 - 2398 .
Cuzick J, Howell A ( 2000 ) . A brief review of the breast cancer prevention trials . European Journal of Cancer vol. 36 , ( SUPPL. 4 )
Cuzick J ( 2000 ) . A brief review of the current breast cancer prevention trials and proposals for future trials . European Journal of Cancer . vol. 36 , 1298 - 1302 .
Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, Clarkson P, Duncan I ( 2000 ) . Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women . British Journal of Cancer vol. 82 , ( 7 ) 1348 - 1352 .
Cuzick J ( 2000 ) . Future possibilities in the prevention of breast cancer - Breast cancer prevention trials . BREAST CANCER RES vol. 2 , ( 4 ) 258 - 263 .
Cuzick J ( 2000 ) . Viruses and cancer . Journal of epidemiology and biostatistics vol. 5 , ( 3 ) 143 - 152 .
Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK et al. ( 1999 ) . HPV testing in primary screening of older women . British Journal of Cancer vol. 81 , ( 3 ) 554 - 558 .
Cuzick J ( 1999 ) . Screening for cancer: Future potential . European Journal of Cancer vol. 35 , ( 5 ) 685 - 692 .
Cuzick J ( 1999 ) . Once-only sigmoidoscopy . Annals of Oncology . vol. 10 ,
Cuzick J ( 1999 ) . Screening for cancer: Future potential . European Journal of Cancer vol. 35 , ( 14 ) 1925 - 1932 .
Cuzick J ( 1998 ) . Screening . Cancer Surveys vol. 33 , 345 - 354 .
Hutchings O, Evans G, Fallowfield L, Cuzick J, Howell A ( 1998 ) . Effect of early American results on patients in a tamoxifen prevention trial (IBIS) [3] . Lancet vol. 352 , ( 9135 )
Cuzick J, Holland R, Barth V, Davies R, Faupel M, Fentiman I, Frischbier HJ, LaMarque JL et al. ( 1998 ) . Electropotential measurements as a new diagnostic modality for breast cancer . Lancet vol. 352 , ( 9125 ) 359 - 363 .
Holli K, Isola J, Cuzick J ( 1998 ) . Low biologic aggressiveness in breast cancer in women using hormone replacement therapy . Journal of Clinical Oncology vol. 16 , ( 9 ) 3115 - 3120 .
Holli K, Isola J, Cuzick J ( 1997 ) . Hormone replacement therapy and biological aggressiveness of breast cancer [3] . Lancet vol. 350 , ( 9092 ) 1704 - 1705 .
Terry G, Ho L, Cuzick J ( 1997 ) . Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type . International Journal of Cancer vol. 73 , ( 5 ) 651 - 655 .
Cuzick J ( 1997 ) . The use of hormone replacement therapy for women with breast cancer: A trial in the advanced disease setting . Endocrine-Related Cancer vol. 4 , ( 3 ) 281 - 283 .
Odunsi K, Terry G, Linda HO, Bell J, Cuzick J, Ganesan TS ( 1996 ) . Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles . International Journal of Cancer vol. 67 , ( 5 ) 595 - 602 .
Thirlaway K, Fallowfield L, Cuzick J ( 1996 ) . The sexual activity questionnaire: A measure of women's sexual functioning . Quality of Life Research vol. 5 , ( 1 ) 81 - 90 .
Cuzick J ( 1996 ) . Chemoprevention of breast cancer with tamoxifen . IARC scientific publications ( 136 ) 95 - 109 .
Londesborough P, Linda HO, Terry G, Cuzick J, Wheeler C, Singer A ( 1996 ) . Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities . International Journal of Cancer vol. 69 , ( 5 ) 364 - 368 .
Cuzick J ( 1996 ) . Medicinal drugs with hormonal activity as chemopreventive agents . IARC scientific publications ( 139 ) 99 - 114 .
Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS ( 1995 ) . Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia . Molecular medicine (Cambridge, Mass.) vol. 1 , ( 2 ) 161 - 171 .
Cuzick J ( 1995 ) . Human papillomavirus infection of the prostate . Cancer Surveys . vol. 23 , 91 - 95 .
Cuzick J, Zito R ( 1994 ) . Genotoxicity of tamoxifen [1] . Journal of Experimental and Clinical Cancer Research vol. 13 , ( 4 ) 417 - 418 .
Terry G, Ho L, Szarewski A, Cuzick J ( 1994 ) . Semiautomated detection of human papillomavirus DNA of high and low oncoaenic potential in cervical smears . Clinical Chemistry vol. 40 , ( 10 ) 1890 - 1892 .
King MM, Hollingsworth A, Cuzick J, Garner RC ( 1994 ) . The detection of adducts in human cervix tissue dna using p-postlabelling: A study of the relationship with smoking history and oral contraceptive use . Carcinogenesis vol. 15 , ( 5 ) 1097 - 1100 .
Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M et al. ( 1994 ) . Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy . Journal of Clinical Oncology vol. 12 , ( 3 ) 447 - 453 .
Cuzick J, Mossman J, Stewart H ( 1994 ) . Cooperative breast cancer trials organized by the United Kingdom co‐ordinating committee on cancer research . Cancer vol. 74 , ( 3 S ) 1160 - 1163 .
Maddox P, Szarewski A, Dyson J, Cuzick J ( 1994 ) . Cytokeratin expression and acetowhite change in cervical epithelium . Journal of Clinical Pathology vol. 47 , ( 1 ) 15 - 17 .
Cuzick J ( 1994 ) . Multiple myeloma . Cancer Surveys vol. 19-20 , 455 - 474 .
Mansell ME, Ho L, Terry G, Singer A, Cuzick J ( 1994 ) . Semi‐quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality . BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 101 , ( 9 ) 807 - 809 .
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M ( 1994 ) . Type-specific human papillomavirus dna in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia . British Journal of Cancer vol. 69 , ( 1 ) 167 - 171 .
Bianchini F, Montesano R, Shuker DEG, Cuzick J, Wild CP ( 1993 ) . Quantification of 7-methyldeoxyguanosine using immunoaffinity purification and HPLC with electrochemical detection . Carcinogenesis vol. 14 , ( 8 ) 1677 - 1682 .
Atkin WS, Cuzick J ( 1993 ) . Screening for colorectal cancer . The Lancet vol. 341 , ( 8861 )
Atkin WS, Northover JMA, Cuzick J, Whynes DK ( 1993 ) . Prevention of colorectal cancer by once-only sigmoidoscopy . The Lancet vol. 341 , ( 8847 ) 736 - 740 .
King MM, Cuzick J, Jenkins D, Routledge MN, Garner RC ( 1993 ) . Immunoaffinity concentration of human lung DNA adducts using an anti-benzo[a]pyrene-diol-epoxide-DNA antibody. Analysis by <sup>32</sup>P-postlabelling or ELISA . Mutation Research/Environmental Mutagenesis and Related Subjects vol. 292 , ( 2 ) 113 - 122 .
Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C et al. ( 1993 ) . Long term effects of tamoxifen. Biological Effects of Tamoxifen Working Party . European Journal of Cancer vol. 29 , ( 1 ) 15 - 21 .
Cuzick J, Baum M, Paterson AHG, Neven P, Lowe DG, Shepherd JH, Nicholson RH ( 1992 ) . Prevention of breast cancer . The Lancet vol. 340 , ( 8834-8835 ) 1550 - 1552 .
Jones MH, Singer A, Jenkins D, Cuzick J, Wolfendale MR, Usherwood MMD, Jones JJ, Balogun-Lynch C ( 1992 ) . Mild cervical dyskaryosis: safety of cytological surveillance . The Lancet vol. 339 , ( 8807 ) 1440 - 1443 .
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M ( 1992 ) . Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer . The Lancet vol. 339 , ( 8799 ) 959 - 960 .
Routledge MN, Garner RC, Jenkins D, Cuzick J ( 1992 ) . <sup>32</sup>P-postlabelling analysis of DNA from human tissues . Mutation Research Letters vol. 282 , ( 3 ) 139 - 145 .
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M ( 1992 ) . HPV in cervical smears [1] . Lancet vol. 340 , ( 8811 ) 112 - 113 .
Cuzick J ( 1992 ) . Methodologic issues in the chemoprevention of breast cancer . Cancer detection and prevention vol. 16 , ( 1 ) 81 - 85 .
Jones MH, Jenkins D, Cuzick J, Wolfendale MR, Jones JJ, Balogun-Lynch C, Usherwood MM, Singer A ( 1992 ) . Mild cervical dyskaryosis: Safety of cytological surveillance . Obstetrical and Gynecological Survey vol. 47 , ( 11 ) 792 - 794 .
Cuzick J, Berridge D, Whitehead J ( 1991 ) . Mammographic dysplasia as entry criterion for breast cancer prevention trials . The Lancet vol. 337 , ( 8751 )
Szarewski A, Cuzick J ( 1991 ) . Authors' reply . BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 98 , ( 7 ) 741 - 743 .
Scholefield JH, Northover JMA, Cuzick J ( 1990 ) . Anal cancer and marital status . British Journal of Cancer vol. 62 , ( 2 ) 286 - 288 .
Cuzick J, Singer A, De Stavola BL, Chomet J ( 1990 ) . Case-control study of risk factors for cervical intraepithelial neoplasia in young women . European Journal of Cancer and Clinical Oncology vol. 26 , ( 6 ) 684 - 690 .
Cuzick J, Routledge MN, Jenkins D, Garner RC ( 1990 ) . DNA adducts in different tissues of smokers and non‐smokers . International Journal of Cancer vol. 45 , ( 4 ) 673 - 678 .
CUZICK J ( 1990 ) . International Time Trends for Multiple Myeloma . Annals of the New York Academy of Sciences vol. 609 , ( 1 ) 205 - 214 .
Garner RC, Cuzick J, Jenkins D, Phillips DH, Hewer A, King MM, Routledge MN ( 1990 ) . Linear relationship between DNA adducts in human lung and cigarette smoking . IARC scientific publications ( 104 ) 421 - 426 .
Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan ICM ( 1990 ) . Long‐term prognostic value of serum β<inf>2</inf> microglobulin in myelomatosis . British Journal of Haematology vol. 75 , ( 4 ) 506 - 510 .
Cuzick J ( 1990 ) . Overview of adjuvant radiotherapy for breast cancer . Progress in clinical and biological research vol. 354 B , 227 - 232 .
Cuzick J, de Stavolal BL, Russell MJ, Thomas BS ( 1990 ) . Vitamin A, vitamin E and the risk of cervical intraepithelial neoplasia . British Journal of Cancer vol. 62 , ( 4 ) 651 - 652 .
Cuzick J, De Stavola BL ( 1989 ) . Autoimmune disorders and multiple meyloma . International Journal of Epidemiology vol. 18 , ( 1 )
Cuzick J, de Stavola B, McCance D, Ho TH, Tan G, Cheng H, Chew SY, Salmon YM ( 1989 ) . A case-control study of cervix cancer in Singapore . British Journal of Cancer vol. 60 , ( 2 ) 238 - 243 .
BARTON SE, SINGER A, JENKINS D, HOLLINGWORTH A, CUZICK J ( 1989 ) . An explanation for the problem of false‐negative cervical smears . BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 96 , ( 4 ) 482 - 485 .
Cuzick J ( 1989 ) . Overview of adjuvant radiotherapy for breast cancer . Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 115 , 220 - 225 .
Cuzick J, Babiker AG ( 1989 ) . Pancreatic cancer, alcohol, diabetes mellitus and gall‐bladder disease . International Journal of Cancer vol. 43 , ( 3 ) 415 - 421 .
Barton SE, Hollingworth A, Maddox PH, Edwards R, Cuzick J, McCance DJ, Jenkins D, Singer A ( 1989 ) . Possible cofactors in the etiology of cervical intraepithelial neoplasia. An immunopathologic study . Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 34 , ( 9 ) 613 - 616 .
Barton SE, Jenkins D, Cuzick J, Maddox PH, Edwards R, Singer A ( 1988 ) . EFFECT OF CIGARETTE SMOKING ON CERVICAL EPITHELIAL IMMUNITY: A MECHANISM FOR NEOPLASTIC CHANGE? . The Lancet vol. 332 , ( 8612 ) 652 - 654 .
Havelock C, Edwards R, Cuzick J, Chamberlain J ( 1988 ) . The organization of cervical screening in general practice . Journal of the Royal College of General Practitioners vol. 38 , ( 310 ) 207 - 211 .
Cuzick J ( 1988 ) . Cervical screening . British Journal of Hospital Medicine vol. 39 , ( 4 )
Cuzick J, De Stavola B ( 1988 ) . Multiple myeloma a case-control study . British Journal of Cancer vol. 57 , ( 5 ) 516 - 520 .
Cuzick J ( 1988 ) . Overview of adjuvant radiotherapy for breast cancer . Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 111 , 105 - 107 .
Cuzick J, Stewart HJ, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G et al. ( 1988 ) . Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer . Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 111 , 108 - 129 .
CAMPION MJ, BROWN JR, MCCANCE DJ, ATIA W, EDWARDS R, CUZICK J, SINGER A ( 1988 ) . Psychosexual trauma of an abnormal cervical smear . BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 95 , ( 2 ) 175 - 181 .
MacLennan ICM, Kelly K, Crockson RA, Cooper EH, Cuzick J, Chapman C ( 1988 ) . Results of the mrc myelomatosis trials for patients entered since 1980 . Hematological Oncology vol. 6 , ( 2 ) 145 - 158 .
Shih WJ, Cuzick J ( 1988 ) . Testing in case-control studies with ordinal exposure variables . Biometrics vol. 44 , ( 3 ) 901 - 905 .
Cuzick J, Boyle P ( 1988 ) . Trends in cervix cancer mortality . Cancer surveys vol. 7 , ( 3 ) 417 - 439 .
Fentiman IS, Balkwill FR, Cuzick J, Hayward JL, Rubens RD ( 1987 ) . A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence . European Journal of Surgical Oncology vol. 13 , ( 5 ) 425 - 428 .
Hollingworth A, Barton SE, Jenkins D, Cuzick J, Singer A ( 1987 ) . Colposcopy of women with cervical HPV type 16 infection but normal cytology . Lancet vol. 2 , ( 8568 )
Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, Lythgoe JP, Prescott RJ ( 1987 ) . Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer . Cancer Treatment Reports vol. 71 , ( 1 ) 7 - 14 .
Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G et al. ( 1987 ) . Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer . Cancer Treatment Reports vol. 71 , ( 1 ) 15 - 29 .
Goh HS, Jass JR, Atkin WS, Cuzick J, Northover JMA ( 1987 ) . Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis . International Journal of Colorectal Disease vol. 2 , ( 1 ) 17 - 21 .
Cuzick J, Erskine S, Edelman D, Galton DAG ( 1987 ) . A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis: A report to the medical research council’s working party on leukaemia in adults . British Journal of Cancer vol. 55 , ( 5 ) 523 - 529 .
Campion MJ, Cuzick J, McCance DJ, Singer A ( 1987 ) . Progressive potential of mild cervical atypia: Prospective cytological, colposcopic, and virologic study . Obstetrical and Gynecological Survey vol. 42 , ( 4 ) 260 - 262 .
Campion MJ, Cuzick J, McCance DJ, Singer A ( 1986 ) . PROGRESSIVE POTENTIAL OF MILD CERVICAL ATYPIA: PROSPECTIVE CYTOLOGICAL, COLPOSCOPIC, AND VIROLOGICAL STUDY . The Lancet vol. 328 , ( 8501 ) 237 - 240 .
Cuzick J, Wang DY, Bulbrook RD ( 1986 ) . THE PREVENTION OF BREAST CANCER . The Lancet vol. 327 , ( 8472 ) 83 - 86 .
JASS JR, ATKIN WS, CUZICK J, BUSSEY HJR, MORSON BC, NORTHOVER JMA, TODD IP ( 1986 ) . The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases . Histopathology vol. 10 , ( 5 ) 437 - 459 .
Bodmer W, Chamberlain J, Cook G, Cuzick J, Draper G, Erskine S, Fisher H, Griffiths R et al. ( 1986 ) . The management of a cervical screening programme: A statement (October 1985) . Journal of Public Health (United Kingdom) vol. 8 , ( 3 ) 179 - 184 .
Clayton D, Cuzick J ( 1985 ) . EM ALGORITHM FOR COX'S REGRESSION MODEL USING GLIM . Journal of the Royal Statistical Society. Series C: Applied Statistics vol. 34 , ( 2 ) 148 - 156 .
Cuzick J, Baum M ( 1985 ) . TAMOXIFEN AND CONTRALATERAL BREAST CANCER . The Lancet vol. 326 , ( 8449 )
Cuzick J ( 1985 ) . A method for analysing case-control studies with ordinal exposure variables . Biometrics vol. 41 , ( 3 ) 609 - 621 .
Cuzick J ( 1985 ) . A wilcoxon‐type test for trend . Statistics in Medicine vol. 4 , ( 1 ) 87 - 90 .
Cuzick J ( 1985 ) . Searching for clusters and associations in cancer epidemiology . Leukemia Research vol. 9 , ( 6 ) 669 - 670 .
Cuzick J, Cooper EH, MacLennan ICM ( 1985 ) . The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis . British Journal of Cancer vol. 52 , ( 1 ) 1 - 6 .
Cuzick J, Cooper EH, MacLennan ICM ( 1985 ) . The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis. (A report to the Medical Research Council's Working Party on leukaemia in adults) . British Journal of Cancer vol. 52 , ( 1 ) 1 - 6 .
Cuzick J ( 1984 ) . A review of semi-parametric models for life histories . IMA Journal of Mathematics Applied in Medicine and Biology vol. 1 , ( 4 ) 323 - 332 .
Fentiman IS, Cuzick J, Millis RR, Hayward JL ( 1984 ) . Which patients are cured of breast cancer? . British Medical Journal vol. 289 , ( 6452 ) 1108 - 1111 .
Cuzick J, Harris R, Mortimer PS ( 1984 ) . PALMAR KERATOSES AND CANCERS OF THE BLADDER AND LUNG . The Lancet vol. 323 , ( 8376 ) 530 - 533 .
Turesson I, Zettervall O, Cuzick J, Waldenstrom JG, Velez R ( 1984 ) . Comparison of Trends in the Incidence of Multiple Myeloma in Malmö, Sweden, and Other Countries, 1950–1979 . New England Journal of Medicine vol. 310 , ( 7 ) 421 - 424 .
Cuzick J ( 1984 ) . A review of semi-parametric models for life histories . Mathematical Medicine and Biology vol. 1 , ( 4 ) 323 - 332 .
Chaudary MA, Millis RR, Hoskins EOL, Halder M, Bulbrook RD, Cuzick J, Hayward JL ( 1984 ) . Bilateral primary breast cancer: A prospective study of disease incidence . British Journal of Surgery vol. 71 , ( 9 ) 711 - 714 .
Cuzick J, Bulstrode JC, Stratton I, Thomas BS, Bulbrook RD, Hayward JL ( 1983 ) . A prospective study of urinary androgen levels and ovarian cancer . International Journal of Cancer vol. 32 , ( 6 ) 723 - 726 .
Goldstein IF, Cuzick J ( 1983 ) . Daily patterns of asthma in New York City and New Orleans: An epidemiologic investigation . Environmental Research vol. 30 , ( 1 ) 211 - 223 .
Cuzick J, Velez R, Doll R ( 1983 ) . International variations and temporal trends in mortality from multiple myeloma . International Journal of Cancer vol. 32 , ( 1 ) 13 - 19 .
Mortimer PS, Harris R, Dawber RPR, Cuzick J ( 1983 ) . Palmar keratoses and internal malignancy . British Journal of Dermatology vol. 109 , ( Suppl. 24 ) 21 - 22 .
Leonard RCF, Cuzick J, MacLennan ICM, Vanhegan RI, Mackie PH, McCormick CV, Knight F, Laing AH et al. ( 1983 ) . Prognostic factors in non-Hodgkin's lymphoma: The importance of symptomatic stage as an adjunct to the Kiel histopathological classification . British Journal of Cancer vol. 47 , ( 1 ) 91 - 102 .
Cuzick J ( 1982 ) . Multiple points of a Gaussian vector field . Zeitschrift für Wahrscheinlichkeitstheorie und Verwandte Gebiete vol. 61 , ( 4 ) 431 - 436 .
Cuzick J ( 1982 ) . The assessment of subgroups in clinical trials . Experientia. Supplementum vol. 41 , 224 - 235 .
Cuzick J ( 1982 ) . Rank tests for association with right censored data . Biometrika vol. 69 , ( 2 ) 351 - 364 .
Lavecchia C, Franceschi S, Cuzick J ( 1982 ) . ALCOHOL AND BREAST CANCER . The Lancet vol. 319 , ( 8272 )
Velez R, Beral V, Cuzick J ( 1982 ) . Increased trends of multiple myeloma mortality in England and Wales: Are the changes real? . Journal of the National Cancer Institute vol. 69 , ( 2 ) 387 - 392 .
Peckham MJ, Tobias JS, Baum M, Berstock DA, Bullimore JA, Cuzick J, Durrant K, Faulder C et al. ( 1982 ) . Letters to the editor . British Journal of Cancer vol. 46 , ( 6 )
Buckman R, Cuzick J, Galton DAG ( 1982 ) . Long‐term survival in myelomatosis; A REPORT TO THE MRC WORKING PARTY ON LEUKAEMIA IN ADULTS . British Journal of Haematology vol. 52 , ( 4 ) 589 - 599 .
Cuzick J, Evans S, Gillman M, Price Evans DA ( 1982 ) . Medicinal arsenic and internal malignancies . British Journal of Cancer vol. 45 , ( 6 ) 904 - 911 .
Goldstein IF, Cuzick J ( 1981 ) . Application of a time-space clustering methodology to the assessment of acute environmental effects on respiratory illnesses . Reviews on Environmental Health vol. 3 , ( 3 ) 259 - 275 .
Cuzick J ( 1981 ) . THYROID DISEASE AND BREAST CANCER . The Lancet vol. 317 , ( 8215 )
Cuzick J ( 1981 ) . Radiation-Induced Myelomatosis . New England Journal of Medicine vol. 304 , ( 4 ) 204 - 210 .
Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL, Millis RR, Cuzick J ( 1981 ) . A prospective study of plasma prolactin levels and subsequent risk of breast cancer . International Journal of Cancer vol. 28 , ( 6 ) 673 - 676 .
Cuzick J, Lindgren G ( 1980 ) . Frequency estimation from crossings of an unknown level . Biometrika vol. 67 , ( 1 ) 65 - 72 .
Cuzick J ( 1980 ) . The Hausdorff dimension of the level sets of a Gaussian vector field . Zeitschrift für Wahrscheinlichkeitstheorie und Verwandte Gebiete vol. 51 , ( 3 ) 287 - 290 .
Leonard RCF, MacLennan ICM, Smart Y, Vanhegan RI, Cuzick J ( 1979 ) . Light chain isotype‐associated suppression of normal plasma cell numbers in patients with multiple myeloma . International Journal of Cancer vol. 24 , ( 4 ) 385 - 393 .